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Abstract 
 
The aim of this study was to assess whether progressively dehydrating Type 1 Diabetes 
Mellitus (T1DM) patients via fluid restriction around exercise affected glucose control 
during and following exercise, compared to euhydrated T1DM patients. It is hoped that 
this study can aid the formation of T1DM-specific fluid intake guidelines around exercise, 
based on alterations in glucoregulation and osmoregulation.  
The fluid restriction protocol induced a mild level of dehydration (1.1% body mass loss 
from pre-exercise measurements). Furthermore, dehydrated subjects displayed 
significantly greater post-exercise serum copeptin concentration (p<0.01), compared to 
resting and euhydrated subjects’ values. There was a trend for a greater glycaemic 
response during exercise and the post-exercise recovery period of the dehydration trial, 
but there were no significant differences in either the interstitial or blood glucose 
responses between trials. Although baseline serum glucagon concentrations were 
significantly different between trials (p<0.01), thereafter there were no significant 
differences between trials at any remaining timepoint. There was a statistically significant 
effect of trial on serum cortisol concentrations (p<0.01), with post-exercise serum cortisol 
concentrations remaining significantly greater during the dehydration trial, compared to 
euhydrated subjects’.  
Up to 48 hours following the dehydration trial, there was a significantly reduced 
prevalence of mild hyperglycaemia compared to the same period following the control 
trial (p<0.01), with a trend for a concomitant increase in euglycaemic interstitial glucose 
measurements. The discrepancies in acute glycaemic control occurred without an 
increased risk of hypoglycaemia, and were not attributable to any significant differences 
in total carbohydrate intake or total units of insulin administered. Further research is 
required to establish the intramuscular and intracellular physiology linking dehydration 
with alterations in whole-body and tissue-specific glucose metabolism. T1DM patients 
must therefore balance the potential short-term benefits of mild dehydration on acute 
glycaemic control, with long-term health consequences associated with regular 
dehydration and elevated vasopressin concentrations.  
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 5 
Introduction 
Patients with Type 1 (insulin-dependent) Diabetes Mellitus (T1DM) who regularly 
participate in exercise of varying mode, intensity and duration display improvements in 
cardio-metabolic health and psychological wellbeing, along with a reduced risk of all-
cause mortality and developing disease-related complications (Chimen et al, 2007; 
Kennedy et al, 2013; Yardley et al, 2014; Riddell et al, 2017). Despite the chronically 
impaired glucoregulation associated with T1DM, the benefits of regular physical activity 
outweigh the immediate risks if appropriate glycaemic management strategies are 
implemented (Riddell et al, 2017). However, there are several challenges and perceived 
barriers to T1DM patients participating in physical activity, including a fear of losing 
glycaemic control around exercise (Lascar et al, 2014; Riddell et al, 2017). Stable, 
regimented glycaemic control is considered by both patients and healthcare professionals 
to be the primary method of effectively managing T1DM (Kennedy et al, 2013; Fava et al, 
2014). 
The elevated circulating glucose concentration (hyperglycaemia) symptomatic of 
poorly controlled T1DM arises due to the immune-mediated destruction of pancreatic 
islet beta cells, which severely or wholly impairs the regulation of endogenous insulin 
secretion (McCrimmon and Sherwin, 2010; Younk et al, 2011; Horton and Subauste, 
2016). T1DM patients are therefore reliant on administration of exogenous replacement 
insulin as a method of managing circulating glucose concentrations. Poorly controlled 
T1DM will result in chronically elevated blood glucose concentrations and elevated 
glycated haemoglobin (HbA1c) levels- a marker of long-term glycaemic control. There is a 
significant positive correlation between each of these outcomes and the risk of 
developing macrovascular complications and long-term disease-specific complications 
including retinopathy, neuropathy and nephropathy (Cryer et al, 2002; Fullerton et al, 
2014). However, attempts to reduce average blood glucose concentrations via intensive 
glycaemic management may concurrently increase the risk of hypoglycaemia arising 
(Cryer et al, 2002; Younk et al, 2011, Fullerton et al, 2014). The exogenous insulin 
administered by T1DM patients is not regulated by the same negative feedback 
mechanism as the endogenous insulin secreted by healthy, disease-free subjects in 
response to a rise in blood glucose (Diedrich et al, 2002; McCrimmon and Sherwin, 2010; 
Younk et al, 2011). As a result, administration of an excessive dose of insulin will likely 
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result in hypoglycaemia. The risk of hypoglycaemia arising in T1DM patients with tight 
glycaemic control may be further exacerbated due to defective pancreatic islet alpha cell 
function, and therefore defective secretion of glucagon (Diedrich et al, 2002; McCrimmon 
and Sherwin, 2010; Younk et al, 2011). Glucagon is the principle counter-regulatory 
hormone secreted as part of the overall homeostatic response to hypoglycaemia, 
whereby the release of glucagon from the pancreatic alpha cells stimulates an increased 
rate of hepatic endogenous glucose production (Cryer, 2006; Yosten, 2018). However, 
there is a progressive decline in alpha cell sensitivity to changes in blood glucose 
concentration in T1DM patients over time, which is thought to arise due to the absence 
of regulatory signalling pathways from the progressively declining pancreatic beta cell 
mass (Cryer, 2006; Hughes and Narendran, 2014; Yosten, 2018). Alpha cell function is 
completely dysregulated with advanced T1DM (>10 years of diagnosis), leading to an 
attenuated rate of glucagon secretion in response to hypoglycaemia, subsequently 
increasing the risk of severe hypoglycaemia arising (McCrimmon and Sherwin, 2010; 
Hughes and Narendran, 2014; Yosten, 2018). Furthermore, there may also be a 
paradoxical increase in glucagon secretion from the alpha cells in a post-prandial state 
with advanced T1DM, potentially leading to further glycaemic fluctuations (Hughes and 
Narendran, 2014; McNeilly and McCrimmon, 2018; Yosten, 2018). In contrast, the 
overcorrection of hypoglycaemia via carbohydrate supplementation may lead to an 
increased prevalence of rebound hyperglycaemia. This may subsequently begin a 
recurring cycle of further glycaemic disturbances with repeated treatment of 
hypoglycaemia, followed by hyperglycaemia.  
 The average incidence of symptomatic hypoglycaemia is estimated at twice per 
week for T1DM patients (McCrimmon and Sherwin, 2010) and negatively affects cognitive 
and cardio-respiratory function. Hypoglycaemia initially arises due to relative systemic 
hyperinsulinemia (administration of an excessive dose of exogenous insulin), combined 
with a defective counter-regulatory physiological response to hypoglycaemia associated 
with advanced T1DM (Cryer, 2006; McCrimmon and Sherwin, 2010; McNeilly and 
McCrimmon, 2018). Research has consistently highlighted that following previous 
hypoglycaemia, including mild asymptomatic episodes, T1DM patients display an 
impaired neuro-endocrine counter-regulatory response to subsequent episodes of 
hypoglycaemia (Diedrich et al, 2002; McCrimmon and Sherwin, 2010; McNeilly and 
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McCrimmon, 2018).  The attenuated glucagon response to hypoglycaemia, coupled with 
the inability to regulate circulating insulin concentrations, is compounded by an 
attenuated sympathetic neural response to hypoglycaemia- namely the decreased 
secretion of catecholamines (Cryer, 2006; McCrimmon and Sherwin, 2010; Mcneilly and 
McCrimmon, 2018). Hypoglycaemia leads to an increase in the glycaemic threshold 
(lower blood glucose concentration) required to stimulate the magnitude of epinephrine 
response to prevent a further decline in blood glucose concentrations during any 
subsequent hypoglycaemic episodes. Furthermore, the sympathetic neural response is 
closely associated with the symptomatic response to hypoglycaemia, which is comprised 
of autonomic (e.g. sweating, palpitations) and neuroglycopenic (e.g. confusion, 
drowsiness) symptoms (Cryer, 2006). T1DM patients may therefore lose the ability to 
recognise the onset of hypoglycaemia due to less prominent symptoms occurring at a 
defined hypoglycaemic concentration (Cryer, 2012; McNeilly and McCrimmon, 2018). The 
delay in recognising and treating the symptoms of hypoglycaemia (Impaired Awareness 
of Hypoglycaemia- IAH) will increase the risk of severe hypoglycaemia arising (McNeilly 
and McCrimmon, 2018). This cluster of attenuated physiological responses to antecedent 
hypoglycaemia is known as Hypoglycaemia Associated Autonomic Failure (HAAF), where 
there is an increased risk of recurrent and/or severe hypoglycaemia due to the impaired 
counter-regulatory responses and impaired awareness of hypoglycaemia (Cryer, 2006; 
Younk et al, 2011). Repeated or severe hypoglycaemic episodes, where external medical 
assistance is required due to physiological and neural dysfunction, may lead to a coma or 
death. However, avoidance of hypoglycaemia over a short duration has a protective 
effect against the development of HAAF and further hypoglycaemia arising (Diedrich et al, 
2002; Younk et al, 2011). T1DM patients must therefore balance the avoidance of 
hypoglycaemia with the aim of attaining the desired level of glycaemic control, which 
may include participation in exercise. 
Longitudinal studies and meta-analyses have shown that regular exercise is 
positively associated with improvements in indices of glycaemic control, including 
reductions in daily insulin requirements (via increased insulin sensitivity and glucose 
tolerance), decreased prevalence of severe hypoglycaemia and increased hypoglycaemia 
awareness (Kennedy et al, 2011; Fullerton et al, 2014; Riddell et al, 2017). Furthermore, 
improvements in insulin delivery and glucose monitoring technology, coupled with 
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differing strategies focusing on improved glucose control via the manipulation of 
exercise-based nutrition and differing exercise modalities, have aided safer participation 
in exercise (Riddell and Perkins, 2006; Horton and Subauste, 2016). There is no consensus 
on the ‘optimal’ type, duration, intensity or mode of exercise to maintain glucose within a 
desired range due to the individual nature of the glycaemic response to exercise (Basu et 
al, 2014; Colberg et al, 2016). There are many differences in the endocrine responses of 
healthy, non-DM individuals and T1DM patients during various modes of exercise, which 
may explain some of the glucoregulatory challenges faced by T1DM patients. In non-
diabetic individuals, there is an immediate reduction in insulin secretion from pancreatic 
beta cells, coupled with an increase in glucagon secretion from the pancreatic alpha cells 
and elevated epinephrine concentrations during the initial stages of moderate intensity 
exercise. Endogenous insulin secretion in T1DM patients is either dysregulated or wholly 
absent, and therefore only the rate of absorption and clearance of exogenous insulin will 
lead to a decline in systemic insulin concentrations. However, the glucagon response 
during exercise is maintained in T1DM patients, provided there is no threat of 
hypoglycaemia arising (Younk et al, 2011). The increased glucagon acts synergistically 
with a gradually increased epinephrine concentration to stimulate an increase in hepatic 
glucose production beyond the rate of muscle glucose uptake. Higher intensity exercise 
or resistance exercise leads to the increased secretion of counter-regulatory hormones 
including cortisol, epinephrine and norepinephrine in both non-DM individuals and T1DM 
patients. The elevated counter-regulatory hormone concentrations may spare hepatic or 
muscle glucose stores, while also transiently increasing the circulating glucose 
concentration. There are a variety of additional exercise-based factors including the 
insulin dosing regime, nutritional intake and training status that T1DM patients must 
consider and manage to minimise significant glycaemic excursions (hypoglycaemia and 
hyperglycaemia), coupled with regularly monitoring circulating glucose concentrations 
(Riddell et al, 2017).  
The fear of hypoglycaemia is the primary barrier to T1DM patients achieving the 
desired level of glycaemic control, while the risk of post-exercise hypoglycaemia arising 
negatively affects T1DM patients’ participation in exercise (Younk et al, 2011; Colberg et 
al, 2016; Riddell et al, 2017). The risk of post-exercise hypoglycaemia is elevated up to 24 
hours following exercise, particularly during the initial overnight period following evening 
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exercise, due to the blunting of counter-regulatory responses to hypoglycaemia 
combined with an increased peripheral insulin sensitivity and glucose uptake respectively 
(Diedrich et al, 2002; Younk et al, 2011; Riddell et al, 2017). Hypoglycaemia often arises 
following exercise due to the failure to adequately reduce the administered exogenous 
insulin dose under conditions of increased insulin sensitivity. T1DM patients must 
consider the gradual decline in glucose concentrations often observed during continuous, 
moderate intensity exercise coupled with the elevated peripheral (skeletal muscle) insulin 
sensitivity due to the contraction-mediated upregulation of GLUT4 translocation (Bussau 
et al, 2006; Campbell et al, 2013). Furthermore, there is an increased requirement to 
replenish the depleted glycogen stores with any ingested carbohydrates, which is aided 
by the increased GLUT4-mediated uptake of glucose (Campbell et al, 2013; Riddell et al, 
2017). Hypoglycaemia prior to commencing exercise may also impair subsequent 
glucoregulation during and following exercise due to the impairments in counter-
regulatory hormone secretion (McCrimmon and Sherwin, 2010; Younk et al, 2011). 
Furthermore, research has also shown that T1DM patients who completed a moderate 
intensity exercise bout displayed an impaired counter-regulatory neuro-endocrine 
response to hypoglycaemia up to 24 hours following the initial exercise bout (Diedrich et 
al, 2002; Younk et al, 2011).  
Inadequate knowledge of strategies to combat any significant changes in glucose 
concentrations during exercise is also considered to be a significant barrier to T1DM 
patient’s participation in physical activity (Colberg et al, 2016; Riddell et al, 2017). To 
date, several different pre-exercise and post-exercise interventions have been primarily 
utilised to prevent post-exercise hypoglycaemia. Bussau et al (2006) showed that 
completion of a short, supramaximal sprint at the culmination of continuous, moderate 
intensity exercise prevented a decline in immediate post-exercise glucose concentrations 
under hyperinsulinemic conditions. Previous research has also successfully manipulated 
pre- and post-exercise basal and bolus insulin regimens (Rhabasa-Lloret et al, 2001; 
Campbell et al, 2013), macronutrient intake (West et al, 2011; Campbell et al, 2014) and 
timing of exercise (Gomez et al, 2015) to prevent post-exercise hypoglycaemia occurring, 
particularly late-onset (nocturnal) hypoglycaemia. However, no research to date has 
assessed the effects of variable fluid intake during and following exercise on T1DM 
patient’s acute or longer-term glycaemic control. Furthermore, all exercise-based 
 10 
interventions to aid post-exercise glycaemic control to date have all advocated adequate 
hydration during and following exercise, based on current population-wide hydration 
guidelines, including diabetic patient population cohorts.  
 There is a dearth of research that has investigated the relationship between fluid 
intake and glucoregulation. High daily water intake has been shown to have an overall 
positive effect on management of Diabetes Mellitus symptoms, whereby there was an 
inverse relationship evident between self-reported daily water intake and the risk of mild 
hyperglycaemia arising (Roussel et al, 2011). Furthermore, Enhörning et al (2019) showed 
that 6 weeks of water supplementation (1.5L increased daily water intake) led to a 
significantly reduced urine osmolality, increased 24 hour urine volume and a significant 
reduction in fasting blood glucose concentration of non-diabetic subjects. However, there 
was no significant difference between Type 2 Diabetes Mellitus (T2DM) patients’ mean 
blood glucose concentration following acute water supplementation (additional 3L of 
water per day), compared to patients who consumed fluids at their habitual rate. The 
multi-directional relationship between fluid intake and glucoregulation is also highlighted 
by the effects of chronic hyperglycaemia, and subsequently excess urinary glucose 
excretion, which stimulates increased glucose-induced osmotic diuresis. The increased 
glucose-induced fluid losses increase the fluid intake requirements for T1DM patients to 
avoid dehydration (Buiote-Stella et al, 2018). No research to date has directly assessed 
the effect of variable fluid intake on changes in T1DM patients’ blood glucose 
concentration at rest or during exercise under euglycaemic conditions. Furthermore, it is 
unclear whether acute or chronic changes in fluid intake are required to stimulate any 
significant differences in acute and longer-term glycaemic control. The physiological link 
between changes in hydration status and glycaemic control is arginine vasopressin, 
commonly known as antidiuretic hormone.  
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T1DM and Vasopressin Physiology 
Arginine vasopressin (AVP; herein referred to as vasopressin) is primarily 
synthesised in the hypothalamus of the brain, where it is then transported into and 
stored within the neurohypophysis (posterior pituitary) for secretion (Ahloulay et al, 
1999; Bankir et al, 2001; Rotondo et al, 2016). The primary function of vasopressin is to 
regulate whole-body fluid balance via the maintenance of serum osmolality within a 
narrow, defined physiological range (Hew-Butler, 2010). The rate of vasopressin secretion 
is primarily determined by fluctuations in serum osmolality detected by peripheral 
osmoreceptors, although relatively greater changes in blood volume or blood pressure 
may also stimulate vasopressin secretion (Bankir et al, 2001; Hew-Butler, 2010). Zerbe et 
al (1985) initially highlighted an elevated basal vasopressin concentration in T1DM 
patients, compared to disease-free subjects. The elevated basal vasopressin 
concentrations of T1DM patients contrasts the polyuria which is symptomatic of 
uncontrolled or undiagnosed T1DM, whereby excess glucose is excreted in the urine 
(glycosuria), stimulating increased fluid losses (Bankir et al, 2001). Elevated vasopressin 
concentrations have been reported in T1DM patients independent of the level of 
glycaemic control (Zerbe et al, 1985; Bouby et al, 2014). The increased vasopressin 
concentration is considered to be a necessary physiological adaptation that stimulates 
increased fluid conservation and minimises further fluid losses via glucose-induced 
osmotic diuresis (Ahloulay et al, 1999; Bankir et al, 2001). Vasopressin released from the 
posterior pituitary binds with V2 receptors- one of three sub-classes of vasopressin 
receptor, located on the basolateral membrane of the renal collecting ducts (Rotondo et 
al, 2016). An osmotically-driven increase in serum vasopressin concentration stimulates 
the endogenous synthesis and insertion of aquaporin-2 channels into the apical 
membrane of the collecting duct, upregulating the rate of renal fluid reabsorption and 
maintaining intracellular fluid composition (see Figure 1) (Hew-Butler, 2010; Rotondo et 
al, 2016; Guelinckx et al, 2016). The increased permeability of the kidney to water and 
sodium reabsorption by the increase in vasopressin concentration results in the 
production of a reduced volume of increasingly concentrated urine.  
Changes in plasma vasopressin concentration have been associated with differing 
fluid intake patterns at rest, under free-living conditions and during exercise across 
previous studies with non-DM subjects. Chronically reduced daily water intake (<1.2L/day 
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of total fluid intake) led to a significant increase in basal vasopressin concentrations 
compared to subjects consuming >2L of water per day (Moscogiuri et al, 2018). 
Furthermore, individuals with habitually low fluid intake display increased circulating 
vasopressin concentrations, decreased 24 hour urine volume and increased urine 
concentration (Guelinckx et al, 2016). In contrast, subjects who consumed a small volume 
of additional water beyond their habitual fluid intake level displayed decreased 
vasopressin concentrations for up to 4 hours post-water consumption, compared with 
subjects who only consumed fluids at a habitual rate. Increased total daily water intake 
over a 1 week period was also associated with a 15% decrease in basal vasopressin 
concentration (Enhorning et al, 2019), while acute water supplementation (additional 
1.5L/day) for 6 weeks led to a significant reduction in plasma vasopressin concentration, 
along with a reduced 24 hour urine osmolality and increased 24 hour urine volume. 
During exercise, studies have consistently shown that partial or total fluid restriction 
around exercise stimulates a significant increase in plasma osmolality, which 
subsequently stimulates an increase in post-exercise vasopressin concentrations, 
compared to euhydrated subjects. McConnell et al (1997) and Melin et al (2001) 
highlighted that a total fluid restriction protocol implemented throughout prolonged, 
continuous exercise led to >2-fold increase in serum vasopressin concentrations and a 
significantly increased plasma sodium concentration (indicative of increased serum 
osmolality), compared to euhydrated subjects. Furthermore, changes in vasopressin 
concentrations were directly aligned with the largest, statistically significant increase in 
both plasma osmolality and body mass loss induced via fluid restriction and exercise in 
the heat, compared to pre-exercise measurements (Montain et al, 1997; Maresh et al, 
2004). It is possible that during exercise, increased vasopressin concentrations and 
plasma osmolality may be more closely related to the exercise intensity rather than an 
individual’s hydration status. However, consumption of 300ml of water prior to maximal 
exercise was shown to impair the anticipated exercise-induced increase in vasopressin 
concentration (Wade and Claybaugh, 1980).  
While the primary osmoregulatory function of vasopressin has been intensively 
studied, an osmotically-mediated increase in vasopressin secretion also stimulates 
several diverse metabolic signalling pathways that may influence glucose homeostasis. 
Exogenous administration of a physiologically excessive vasopressin dose leads to a 
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transient increase in circulating glucose concentration (Abu-Basha et al, 2002). The 
release of vasopressin is not regulated by an increased requirement for elevated glucose 
production, but the potential increase in glucose output mediated by vasopressin may 
subsequently affect the osmotically-induced release of vasopressin (Thompson et al, 
1989). Figure 1 outlines the various interactions of vasopressin secreted under 
hypohydrated conditions (increased plasma osmolality, or large increase in blood 
pressure/reduction in blood volume) with the differing receptors and subsequent 
proposed effects on whole-body glucose metabolism. V1a receptors are present on both 
the liver and adrenal gland, where vasopressin binds and stimulates an upregulated rate 
of hepatic glucose production and increases adrenal cortisol secretion respectively 
(Perraudin et al, 1993; Mavani et al, 2015). V1b receptors are present on the pancreatic 
islet alpha cells, where vasopressin secretion stimulates the release of glucagon and 
subsequently affects hepatic glucose metabolism (Mavani et al, 2015; Rotondo et al, 
2016). Furthermore, V1b receptors are also present on the anterior pituitary, where 
vasopressin either augments the corticotrophin-releasing hormone (CRH)-stimulated 
increase in adrenocorticotropin-releasing hormone (ACTH), or directly stimulates the 
secretion of ACTH (Mavani et al, 2015). ACTH secretion ultimately stimulates cortisol 
release from the adrenal cortex, leading to an increased blood glucose concentration.   
The secretion of cortisol from the adrenal cortex leads to both short-term and 
long-term effects on whole-body glucose metabolism. In response to an acute stress, 
cortisol exerts various non-genomic effects that lead to a transient increase in circulating 
glucose concentrations. For example, cortisol stimulates glucose intolerance in peripheral 
tissues due to the suppression of insulin-mediated skeletal muscle glucose uptake 
(Zarkovic et al, 2008; Kuo et al, 2015). Furthermore, cortisol secreted in response to an 
acute stress has also been shown to rapidly regulate the actions of the Hypothalamic 
Pituitary Axis (HPA) via negative feedback mechanism, leading to the suppression of 
corticotropin-releasing hormone and ACTH secretion respectively and subsequently 
impairing a further increase in cortisol (Groeneweg et al, 2012). In contrast, the tissue-
specific changes in glucose metabolism mediated by an increase in cortisol secretion tend 
to arise following transcription-dependent pathways, which may lead to a delay of 
between 15 minutes to several hours (Groeneweg et al, 2012; Kuo et al, 2013). Cortisol 
binds with a cytosolic glucocorticoid receptor, which then travels into the nucleus and 
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associates with cortisol-specific gene sequences that promote the necessary changes in 
gene transcription to account for the effects of cortisol on glucose metabolism 
(Groeneweg et al, 2012; Kuo et al, 2013; Kuo et al; 2015). A short-term increase in cortisol 
secretion stimulates an increase in hepatic gluconeogenesis, concurrently stimulates 
increased skeletal muscle glycogenolysis with epinephrine and may impair insulin 
signalling (Andrews and Walker, 1999; Kuo et al, 2013). Research has consistently shown 
that cortisol activates a transcriptionally-mediated upregulation of the key enzymes and 
molecules involved in each pathway affecting glucose metabolism (Kuo et al, 2015). 
However, chronically elevated cortisol concentrations symptomatic of a prolonged stress 
response may lead to the development of hyperglycaemia and whole-body insulin 
resistance.  Research to date has not elucidated whether vasopressin-mediated 
alterations in ACTH secretion and subsequent cortisol secretion are non-genomic or 
transcription-dependent following acute osmotic stress.  
Vasopressin receptors (V1a) present on isolated hepatocytes have been shown to 
stimulate increased rates of gluconeogenesis and glycogenolysis in vitro (Whitton et al, 
1978; Kirk et al, 1979). Vasopressin mimics the effects of glucagon secretion by 
stimulating an increase in hepatic glucose production via the V1a receptor subtype, while 
glucagon binds with a different receptor sub-type on the pancreatic alpha cells before 
stimulating increased endogenous glucose production. However, no research to date has 
assessed the changes in the rate of hepatic glucose production at a whole-body level with 
administration of variable vasopressin concentrations or differences in fluid intake 
patterns. In contrast, much of the research investigating the effects of V1a receptor 
activation has focused on the direct release of cortisol from the adrenal cortex following 
vasopressin secretion (indicative of acute osmoregulatory stress). Perraudin et al (1993) 
highlighted a dose-dependent increase in cortisol secretion with increased exogenous 
administration of vasopressin. Furthermore, analysis of the pattern of vasopressin-
mediated adrenal cortisol release via V1a receptors highlighted a biphasic response. 
Vasopressin secretion stimulated a short-term, rapid increase in cortisol concentrations 
before gradually declining and plateauing at around basal levels. The biphasic cortisol 
response to the elevated vasopressin concentration is believed to arise due to V1a 
receptor desensitization rather than an increase in the rate of vasopressin degradation 
(Perraudin et al, 1993). Previous studies have also postulated that the elevated basal 
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vasopressin concentration associated with T1DM may lead to a desensitization to the 
metabolic and/or osmoregulatory functions of vasopressin, including the effects of 
vasopressin on cortisol secretion and subsequent effect on glucose homeostasis 
(Ahloulay et al, 1999; Bankir et al, 2001).  
 
 
Figure 1: Schematic of the osmoregulatory function and metabolic signalling pathways 
stimulated by the release of vasopressin under conditions of low fluid intake in Type 1 
Diabetes Mellitus patients. Vasopressin is released and subsequently interacts with three 
specific sub-classes of receptor located on various tissues. Vasopressin’s primary function 
is to promote an increased rate of renal fluid reabsorption, but is also thought to be 
responsible for elevated blood glucose concentrations through increased hepatic glucose 
output mediated via increased glucagon and cortisol secretion. Although vasopressin has 
been shown to stimulate both insulin and glucagon release from the pancreatic alpha and 
beta cells respectively, endogenous insulin production is absent in Type 1 Diabetes 
Mellitus patients. Adapted from Rotondo et al (2016) and Moscogiuri et al (2018).  
 
V1b receptors are located on both the pancreatic islet alpha and beta cells 
respectively, whereby an increase in vasopressin concentration typically stimulates the 
release of both glucagon (alpha cell) and insulin (beta cell) in healthy, non-DM subjects 
(Mavani et al, 2015). There is no net effect on glucose metabolism due to the concurrent 
secretion of the counter-balancing hormones. However, the autoimmune destruction of 
the pancreatic beta cells, and subsequent absence of endogenous insulin secretion in 
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T1DM patients, often leads to hyperglucagonemia arising which may further impair T1DM 
patients’ glucose metabolism (Bankir et al, 2001; Yibchock-anun et al, 2004). Glucagon 
secretion is usually inhibited by the actions of insulin, however the increased endogenous 
glucose production stimulated by the release of glucagon is unimpaired due to the 
absence of counter-balancing insulin production (Bankir et al, 2001; Mavani et al, 2015). 
It is believed that an increase in vasopressin concentration within a ‘physiological range’ 
(3-30pmol/L) is likely to stimulate increased glucagon secretion and subsequently 
increase hepatic glucose output (Mavani et al, 2015). Abu-Basha et al (2002) and Yibchok-
anun et al (2004) demonstrated a dose-dependent vasopressin-mediated increase in 
glucagon secretion from pancreatic alpha cells via V1b receptor activation in vitro based 
on this concentration range. Glucagon release via V1b receptor binding augments the 
increased hepatic glucose output stimulated independently via vasopressin binding with 
the V1a receptor subtype on the liver. Vasopressin can therefore stimulate an increased 
hepatic glucose output even with decreased expression or binding affinity of V1b 
receptors (Mavani et al, 2015). Studies to date that have investigated the primary effect 
of the vasopressin-mediated increase in glucagon concentration have shown contrasting 
results, with administration of pharmacological doses of vasopressin leading to no change 
in serum osmolality but increased hepatic glycogenolysis via elevated glucagon 
concentrations (Spruce et al, 1985). In contrast, Ahloulay et al (1999) highlighted an 
increased rate of hepatic gluconeogenesis associated with an increased vasopressin-
mediated glucagon concentration in T1DM patients following a hyperosmotic stimulus at 
rest. However, no research to date has assessed changes in vasopressin-mediated 
glucagon concentrations following alterations in whole-body osmoregulation induced by 
exercise and fluid restriction.  
The physiological relationship between vasopressin, glycaemic control and glucagon 
has proven equivocal in research to date, due to the divergence in methods of altering 
whole-body fluid balance and recruitment of healthy, non-DM patients. Following the 
withdrawal of insulin, severe hypohydration via pharmacological treatment and fluid 
restriction led to a significantly increased fasted glucose response, which was partly 
attributable to an increase in the fasted glucagon concentration (Burge et al, 2001). In 
contrast, Enhorning et al (2019) highlighted that prescription of 3L/day of additional 
water intake for 1 week led to a significantly reduced vasopressin and glucagon 
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concentration in those with habitually low fluid intake only, but there was no overall 
effect on plasma glucagon concentration or circulating glucose concentrations. It is 
therefore unlikely that manipulations in habitual fluid intake and/or hydration status will 
affect non-DM patients glucoregulation, due to the functional secretion of insulin in 
response to the elevated hepatic glucose output stimulated by the release of glucagon 
following vasopressin stimulation (Carroll and James, 2019). The effect of the elevated 
basal vasopressin concentration in T1DM patients on the vasopressin-mediated glucagon 
response at rest, around exercise or with variable fluid intake has not been studied to 
date, therefore there is no defined physiological glucagon concentration range for T1DM 
patients.  
V1b receptors are also present at the anterior pituitary, where the secretion and 
binding of vasopressin has been shown to regulate ACTH release via divergent signalling 
pathways in response to both acute and chronic stress, that may include changes in 
hydration status. Vasopressin primarily augments the release of ACTH that is directly 
stimulated via the actions of CRH, which is synthesized and released from the 
hypothalamus (Goncharova, 2013; Rotondo et al, 2016). Infusion of CRH and AVP in 
individuals with reduced glucose tolerance (reduced peripheral insulin sensitivity) led to 
increased pituitary ACTH secretion, and elevated serum cortisol concentrations that led 
to hyperglycaemia arising (Mavani et al, 2015). Vasopressin alone may also directly 
stimulate the release of ACTH from the anterior pituitary via binding with the V1b 
receptor subtype, but the secretion of CRH does not potentiate the effects of vasopressin 
on ACTH secretion (Rotondo et al, 2016). ACTH stimulates the adrenal cortex- namely the 
zona fasciculata, to release adrenocortical glucocorticoids (cortisol). The increase in 
cortisol secretion subsequently leads to an increased rate of hepatic glucose output due 
to upregulated glucagon-mediated gluconeogenesis (Moscogiuri et al, 2016; Enhorning et 
al, 2017). The interaction between CRH, vasopressin and ACTH release is stressor-specific, 
where an acute or transient stress response to e.g. insulin-induced hypoglycaemia is 
predominantly mediated by vasopressin and CRH acting synergistically to stimulate ACTH 
release (Koshimizu et al, 2012; Goncharova, 2013). In contrast, regular/chronic external 
stress is thought to lead to the upregulation of the actions of vasopressin alone on ACTH 
release via pituitary V1b receptors (Goncharova, 2013; Rotondo et al, 2016). 
Furthermore, the vasopressin-induced release of ACTH, and subsequently cortisol, via 
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direct V1b receptor stimulation is opposed to negative feedback regulation, in contrast to 
CRH-induced ACTH release (Mavani et al, 2015; Moscogiuri et al, 2016). Pituitary V1b 
receptor expression is upregulated in the presence of increased cortisol concentrations, 
which also highlights the importance of the vasopressin-mediated cortisol response to 
chronic stress. Taken together, it is possible, although unproven in research to date, that 
the supraphysiological vasopressin concentration associated with T1DM may stimulate 
excessive ACTH secretion and subsequent cortisol secretion following changes in whole-
body osmoregulation. Elevated plasma vasopressin concentrations have been associated 
with an increased risk of impaired glucose tolerance and development of insulin 
resistance in T2DM patients due to the excessive stimulation of ACTH release by 
vasopressin, leading to elevated cortisol concentrations that impair glucose uptake and 
utilization in peripheral tissues (Moscogiuri et al, 2016).  
Evidence of the association between hydration status, cortisol secretion and 
glycaemic control is based primarily on the results of observational studies, including 
research highlighting that low (<1.2L water intake/day) habitual water intake has been 
shown to result in elevated plasma cortisol levels compared to high (>2L water/day) 
volume drinkers (Moscogiuri et al, 2016). Johnson et al (2017) reported a significantly 
increased circulating cortisol concentration during an oral glucose tolerance test (OGTT) 
when T2DM patients were severely hypohydrated, compared to euhydrated subjects 
completing the OGTT. No measurement of changes in vasopressin or copeptin were 
undertaken, but the increased cortisol concentration was associated with increased 
plasma osmolality, increased plasma sodium concentration and increased urine 
osmolality. Each variable is indicative of increased vasopressin secretion, and is believed 
to stimulate the release of cortisol. The results of the study concur with those of Burge et 
al (2001), however subjects in both studies were withdrawn from insulin administration 
and circulating cortisol concentrations were sampled under fasted conditions. Yadawa et 
al (2016) is the only study to date that has assessed the vasopressin-mediated HPA 
neuroendocrine axis response to varying levels of fluid intake. The authors concluded 
that as CRH-mediated ACTH release was unchanged during water deprivation but 
vasopressin-mediated ACTH secretion was increased in vitro, CRH-mediated ACTH 
secretion does not have any functional role during osmotic stress including fluid 
deprivation. While it is important to note that results of in vitro research may not be 
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applicable when assessing the whole-body neuro-endocrine response to e.g. cellular 
stress following fluid restriction, research to date has consistently shown that chronically 
elevated ACTH concentrations arise following vasopressin directly stimulating the 
pituitary V1b receptors, with no increase in CRH-mediated ACTH secretion (Aguilera and 
Rabadahn-Diehl, 2000; Goncharova, 2013; Rotondo et al, 2016). However, Aguilera and 
Rabadahn-Diehl (2000) reported a decrease in vasopressin-mediated ACTH secretion 
following 2% water deprivation, which suggests osmotic stimulation may require a 
concomitant CRH- and vasopressin-mediated ACTH response. It is currently unclear 
whether the vasopressin-mediated ACTH/cortisol secretion is solely responsible for the 
stress response to acute fluid restriction or chronic osmotic-related stress at a whole-
body level. Furthermore, the effect, if any, of the elevated basal vasopressin 
concentration associated with T1DM patients on the endocrine response to variable fluid 
intake has yet to be investigated.  
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Effect of Dehydration on Substrate Metabolism 
Acute fluid restriction not only results in significant alterations in vasopressin 
concentration, and subsequently fluctuations in metabolic hormone concentrations, but 
has also been consistently shown to affect whole-body substrate metabolism. A series of 
studies by Logan-Sprenger et al (2012, 2015) showed that mild dehydration of up to 3% 
initial body mass is associated with increased carbohydrate oxidation over the duration of 
submaximal continuous exercise, as indicated by elevated Respiratory Exchange Ratio 
(RER) values, the total amount of carbohydrate oxidised and the rate of carbohydrate 
oxidation respectively. Fallowfield et al (1996) initially highlighted a significantly greater 
proportion of the total energy expenditure accounted for via carbohydrate oxidation 
when participants were fluid restricted during submaximal exercise, compared to 
euhydrated participants. The increased reliance on carbohydrate oxidation throughout 
exercise was also evident when assessing substrate metabolism responses of a single 
exercising leg when fluid restricted during exercise, compared to euhydrated participants 
(Gonzalez-Alonso et al, 1999).The results of research undertaken by Hargreaves et al 
(1996), Gonzalez-Alonso et al (1999) and Fernandez-Elias et al (2015) respectively, concur 
with the overall increase in carbohydrate oxidation associated with exercise-induced 
dehydration, whilst also detailing a significantly greater rate of skeletal muscle 
glycogenolysis over the duration of exercise with variable degrees of dehydration 
induced. In contrast, despite Logan-Sprenger et al (2013) also demonstrating a 
significantly increased rate of intramuscular glycogen utilisation in recreationally active 
subjects during exercise, there were no significant differences in either the whole-body 
rate of carbohydrate utilization, RER values or the total amount of carbohydrate oxidised. 
The discrepancies in results between studies were attributed to varied training status, 
although the physiological mechanisms responsible for the increased skeletal muscle 
glycogenolysis under hypohydrated conditions remain unclear (Logan-Sprenger et al, 
2012; Logan-Sprenger et al, 2015; Fernandez-Elias, 2015). No study to date has assessed 
the fluctuations in substrate metabolism of T1DM patients at a whole-body or tissue-
specific level during exercise or with variable fluid intake protocols.  
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Fluid Intake and Copeptin 
Although much of the research to date has sought to assess the relationship between 
glycaemic control and vasopressin-mediated endocrine responses, studies have instead 
measured circulating copeptin concentrations as an indicator of changes in vasopressin 
and overall whole-body osmoregulation (Szinnai et al, 2007; Moscogiuri et al, 2016). 
Analysis of changes in vasopressin concentration are extremely difficult to measure due 
to the short half-life of vasopressin and rapid clearance rate via urinary excretion, 
typically resulting in a low plasma vasopressin concentration (Enhorning et al, 2010; 
Mavani et al, 2015). Vasopressin has a greater molecular weight compared to copeptin, 
which leads to a reduced rate of renal reabsorption following glomerular filtration and 
subsequently a greater clearance rate (Bankir, 2001). In contrast, copeptin is released in 
equimolar amounts from the posterior pituitary with vasopressin, as it synthesised from 
the pre-cursor vasopressin molecule, and is unimpaired by molecule instability or half-life 
duration (Enhorning et al, 2010). A validated sandwich immunoluminometric assay has 
been developed that aids the successful measurement of serum copeptin concentrations, 
which is present at greater concentrations compared to vasopressin (Fenske et al, 2009). 
Several longitudinal studies have shown a direct, positive association between plasma 
copeptin concentrations and prevalence of T2DM, independent of typical diabetes risk 
factors (Enhorning et al, 2010). Furthermore, plasma copeptin concentrations are 
statistically correlated with changes in water intake and inversely associated with 24-hour 
urine volume (Moscogiuri et al, 2016). To date, research has tended to crudely assess 
glycaemic control via fasted blood glucose concentrations relative to serum copeptin 
concentrations, but no study to date has detailed the transient fluctuations in copeptin 
concentration with short-term changes in fluid intake, including around exercise.  
Currently, there are no available fluid intake guidelines specific to T1DM patients 
around exercise. Instead, generalized population-wide guidelines that recommended 
sufficient replacement of exercise-induced fluid losses and maintenance of a euhydrated 
status prior to beginning exercise are utilized (Colberg et al, 2016; Riddell et al, 2017). 
Furthermore, there are no glucoregulatory considerations in the current guidelines, 
whereby impaired glucoregulation that may arise with differing rates of fluid intake will 
lead to the development of T1DM-specific health complications. No research to date has 
directly assessed the effect of variable fluid intake on T1DM patient’s osmoregulatory 
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function, which inhibits the formation of accurate guidelines around fluid intake. 
Furthermore, despite the elevated basal vasopressin concentration associated with T1DM 
patients, there has been no research conducted assessing the physiological impact of the 
previously reported elevated vasopressin at rest or during exercise, and the subsequent 
fluid intake requirement for patients with T1DM. Based on the results of mostly 
observational research to date, it is unclear whether the supraphysiological basal 
vasopressin concentration associated with T1DM may alter the osmotic threshold for 
vasopressin secretion and subsequently affect the vasopressin-mediated renal and 
metabolic response to variable fluid intake.   
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Aim of the Study 
The aim of the current study was to assess whether progressively dehydrating Type 1 
Diabetes Mellitus patients via restricting fluid intake during and immediately following 
exercise affects short-term glycaemic control, compared to a euhydrated condition. 
Furthermore, the secondary aim of this study was to determine whether the anticipated 
alterations in whole-body osmoregulation and subsequent effects on glucose metabolism 
between euhydrated and mildly dehydrated trial were evident when assessing each 
T1DM patient’s acute glycaemic control up to 48 hours following each experimental trial.  
 
Study Hypothesis 
It was hypothesised that the increased vasopressin concentration associated with fluid 
restriction during the progressive dehydration trial would stimulate a variety of 
vasopressin-mediated cellular signalling pathways, resulting in an upregulated endocrine 
response compared to euhydrated subjects. The osmotically-induced increase in 
concentrations of metabolic hormones, including glucagon and cortisol, are thought to 
promote an increased rate of endogenous glucose production and could subsequently 
lead to an elevated glycaemic response during and following exercise. Furthermore, with 
reference to the potentially augmented glycaemic response around exercise with 
progressive dehydration, it was hypothesised that acute glycaemic control in the 48 hours 
post-dehydration trial would likely be compromised. It is thought that T1DM patients will 
experience increased glycaemic variability due to compromised glycaemic management 
regimens following the proposed impairment of glucoregulation with mild dehydration, 
compared to the same period following the control (euhydration) trial. 
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Methodology 
Eleven patients (n=7 males, n=4 females) with Type 1 Diabetes Mellitus were 
initially recruited for participation in the study via the National Health Service (NHS) Forth 
Valley Royal Hospital and the University of Stirling respectively. Participants were eligible 
to take part in the study if they were between 18-60 years of age, had been diagnosed 
with Type 1 Diabetes for at least 1 year, regularly completed aerobic exercise (3 times 
per week) and had good-to-moderate glycaemic control. Glycaemic control was assessed 
via the patient’s self-reported HbA1c level (6.4%-9%) within the last 6 months, coupled 
with the use of the Diabetes Self-Management Questionnaire (DSMQ) (Schmitt et al, 
2013; Appendix 3); a multi-component assessment tool which has been utilized as an 
accurate indicator of glycaemic management. Prospective participants who were 
pregnant or planning pregnancy, suffered from Type 1 Diabetes related complications; 
including retinopathy and a diminished ability to recognize the autonomic or 
neuroglycopenic symptoms of hypoglycaemia arising (Impaired Awareness of 
Hypoglycaemia), or had been diagnosed with a cardio-respiratory or further metabolic 
disorder, were excluded from the study. Furthermore, participants who had suffered a 
major hypoglycaemic episode within the previous 6 weeks were also excluded from 
participating in the study. A major episode was considered to be a scenario where the 
patient was unable to self-administer the necessary corrections for hypoglycemic values 
due to neurological dysfunction (International Hypoglycaemia Study Group, 2017). 
Of the participants recruited, both continuous subcutaneous insulin delivery (n=7) 
and multiple daily insulin injections (n=4) were used as methods of daily short- and long-
acting insulin administration. The participants were required to have been consistently 
employing their chosen insulin administration method for at least 6 months prior to 
commencing participation in the study. There were no inclusion criteria regarding the 
exogenous insulin analogues participants were administering as part of their usual basal-
bolus insulin regimen.  
Following written and verbal explanation of the study design and procedures to 
be undertaken during each experimental trial, all participants provided written, fully 
informed consent to participate. All prospective participants were required to complete 
the DSMQ along with a standardized Pre-Participation Health Screening Questionnaire (P-
PHSQ), which was adapted for the purposes of this study. This questionnaire allowed for 
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the identification of individuals who may be at risk of aggravating pre-existing medical 
conditions through study participation. The study received approval from the National 
Health Service West of Scotland Research Ethics Committee 4 (Rec no. 17/WS/0003; ID: 
217607) and the University of Stirling NHS, Invasive and Clinical Research Ethics 
Committee. All study procedures were conducted in accordance with the guidelines laid 
down in the 2013 Declaration of Helsinki. 
The study required participants to attend the laboratory 4 times. First, an 
incremental ramp exercise test to exhaustion was completed, followed by a 
familiarisation session and two main experimental trials; one control trial and one 
progressive dehydration trial. The familiarization session and the respective experimental 
trials consisted of a one hour exercise protocol at a continuous workload on a stationary 
cycle ergometer, followed by a two-hour post-exercise recovery period. The study was a 
within-subject design, with trial order assigned in a randomized, crossover manner. The 
trial order was randomized using an online latin square crossover-based randomization 
scheduling tool, with participants matched to the trial based on their individually 
assigned participant ID when written consent to participate was obtained. There was at 
least 48 hours between the VO2max test and familiarization session, with the subsequent 
experimental trials separated by at least 7 days. The overall study timeline can be seen in 
Figure 2.
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Figure 2: Overall study timeline including the initial aerobic capacity test, familiarisation session and each of the two main experimental trials. 
Details of the flash interstitial glucose monitor fittings (FreeStyle Libre™; Abbott Technologies, California) are also outlined. Each monitor was 
applied 48 hours prior to the respective experimental trials and continuously collated interstitial glucose concentrations during, and up to 48 
hours following, each experimental trial. Each interstitial glucose monitor was removed 5 days following each experimental trial.  
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Study Design 
Visit 1- Ramp Test to Exhaustion 
Participants were requested to arrive to the laboratory for their initial incremental 
ramp test to exhaustion in a well hydrated state (~500ml water 60 minutes prior to 
arrival) and having fasted for at least 4 hours. Upon arrival, the participant was asked to 
void the contents of their bladder and bowels ahead of recording their near-nude 
(underwear only) initial body mass. Participants were fitted with a heart rate monitor 
(Polar, Sweden) and the seating position on the stationary electronically-braked cycle 
ergometer (Lode Excalibur, Netherlands) was also adjusted and recorded to ensure the 
ergometer setup was consistent throughout the remaining trials. Participants were only 
cleared to commence the ramp test protocol if their capillary glucose value; assessed via 
finger prick technique, was within a specified range (5-11.9mmol/L), based on the 
guidelines for exercise detailed in Colberg et al (2016).  
The test protocol itself was similar to that described by Nevill et al (2005). Briefly, 
participants began exercising at a gender-specific pre-selected wattage (50 watts for 
females, 100 watts for males). Throughout the test, participants were fitted with a 
mouthpiece for continued breath-by-breath online expired gas analysis (OxyCon Pro, 
Jaeger, Germany). Following a 5 minute warm-up and allowing the participant to regulate 
their breathing rate using the mouthpiece, participants were then asked to begin 
pedaling at their desired cadence which they could maintain throughout the duration of 
the test. Following the completion of each one minute stage, the workload increased in 
gender-specific increments (20 watts/min for females, 25 watts/min for males) until the 
participant could no longer complete the stage workload. The online expired gas analysis 
data were subsequently used to determine each participant’s maximal aerobic capacity 
(VO2max), defined as the highest average 30-second oxygen uptake (VO2 ml/kg/min-1) 
value. These data were also used to calculate the workload requirements for the 
remaining experimental trials, where the aim was for participants to complete the 
exercise protocol at a set workload (60% of their maximal aerobic capacity).  
 
Pre-trial Standardization 
Participants were asked to complete a 48-hour dietary intake and exercise diary 
before arriving at the laboratory for their familiarisation session and return this to the 
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investigator. Ahead of the remaining experimental trials, the participants were asked to 
replicate this dietary intake and exercise pattern as closely as possible, and to include any 
necessary hypoglycaemia corrections. Participants arrived to the familiarisation session, 
and for all subsequent experimental trials, in an overnight fasted state (from 10 hours 
prior to arrival) and having refrained from alcohol, tobacco and caffeine consumption and 
moderate-vigorous exercise in the previous 24 hours. Participants were also asked to 
disclose whether they had suffered from a major hypoglycaemic episode between trials, 
which was defined as a blood glucose concentration <3mmol/L, leading to neurological or 
physiological dysfunction that required immediate medical assistance. If the participant 
was found to have suffered from such an episode, they were excluded from further 
participation in the study. Furthermore, details of any additional insulin or carbohydrate 
requirements to treat either mild hypoglycaemia or hyperglycaemia in the hours 
immediately preceding the trial, which may have accounted for discrepancies in 
glycaemic response as the experimental trial progressed, were collected prior to 
commencing each trial. The laboratory temperature was maintained at a constant value 
throughout all experimental trials.   
48 hours before each of the two main experimental trials commenced, 
participants were fitted with a flash interstitial glucose monitor (FreeStyle Libre) on 
their left arm, as per manufacturer instructions. The flash glucose monitors were utilized 
to collate both within-trial interstitial glucose data and ambulatory interstitial glucose 
data prior to, immediately following, and in the two days following each experimental 
trial.  
 
Visit 2- Familiarisation session 
At least 48 hours following the VO2max test, participants arrived at the laboratory 
for their familiarization session. The familiarization session was primarily employed to 
ensure that participants could effectively complete the exercise protocol at the 
calculated workload. Furthermore, it allowed the participants to ensure that the required 
adjustments to their basal insulin and the insulin bolus administered for the breakfast 
provided (26g carbohydrate; ~0.4 g/kg-1 body mass, 164kcals) were appropriate for the 
maintenance of stable glycaemia during the upcoming exercise period. Participants 
voided their bladder and bowels before their near-nude body mass was measured. This 
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body mass value, along with a post-familiarisation trial body mass measurement, was 
used to estimate fluid requirements to match sweat losses when completing the exercise 
protocol. This was to ensure that participants remained euhydrated on the control trial.  
The exercise protocol consisted of a 60 minute continuous exercise workload with 
venous blood samples, glucose monitoring and expired gas analysis completed at 15 
minute intervals. During the familiarisation session, only capillary glucose concentration 
was obtained, via finger prick technique. Water was also provided in a fixed volume every 
15 minutes based on the participant’s estimated sweat rate. Upon completing the 
exercise protocol, participants removed all equipment, before towel drying and voiding 
their bladder prior to a post-exercise near-nude body mass measurement. Following the 
completion of the familiarization session, the volume of fluid was adjusted for the 
subsequent control experimental trial if the participant’s body mass had significantly 
changed from the pre-exercise value after completion of the exercise protocol.  
Participants remained in the laboratory for a further 2 hour post-exercise 
recovery period. During this time, further capillary glucose measurements, along with 
blood and urine sampling respectively, were undertaken. The participants were required 
to be at minimal risk of a hypoglycaemic episode immediately following the trial 
(>5mmol/L), as determined via capillary blood glucose measurement, before they were 
authorized to leave the laboratory.  
 
Visit 3-4- Experimental Trials 
 Participants reported to the laboratory at least 5 days following the familiarisation 
session to complete the first of two main experimental trials. Ahead of each experimental 
trial, participants were encouraged to maintain a euhydrated state pre-trial by consuming 
only water overnight where possible, and upon awakening up to 1 hour prior to arrival at 
the laboratory. Participants were required to bring a first-morning urine sample to the 
laboratory, from which an aliquot was retained for subsequent analysis.  
Following the initial near-nude body mass measurement having voided their 
bladder and bowels, participants were cannulated to allow for efficient blood sampling to 
occur throughout the exercise and post-exercise periods respectively. They were asked to 
lie in a supine position on the bed within the laboratory, whereby a 20-gauge venous 
cannula was then inserted into an antecubital vein of their chosen arm. A baseline (6ml) 
 30 
blood sample was drawn following insertion of the cannula. The patency of the cannula 
was maintained by using pre-prepared saline solution (0.9% BD PosiFlush™ 3ml Saline 
Syringe). The flushing procedure was repeated after every blood sample drawn 
throughout the experimental trial. A total of 11 blood samples were obtained across each 
trial, including one obtained upon initial arrival to the laboratory (6ml) and immediately 
pre-exercise (2ml) respectively.  Further 2ml blood samples were obtained at 15 minute 
intervals during exercise, and at 15 and 45 minutes post-exercise respectively. A large 
blood sample (6ml) was drawn immediately upon the completion of the exercise protocol 
(0hrs post-exercise), with further large blood samples drawn at 30 minute intervals 
during the initial hour of the post-exercise recovery period, and at 2 hours post-exercise.  
Participants were provided with a standardized breakfast prior to beginning 
exercise, which consisted of a portion of instant porridge (Original Instant Porridge Pot, 
Quaker Oats) containing a fixed amount of carbohydrates and with a fixed volume of 
fluid added (175ml). In circumstances where a participant was intolerant to lactose or 
gluten respectively, we provided a quantity of Gluten-Free Oats which matched the 
carbohydrate content of the porridge pots, with the same volume of fluid also used in 
preparation. The participants were encouraged to individually manage the dose of short-
acting insulin administered to compensate for the carbohydrates consumed during the 
breakfast, provided they replicated this during all subsequent trials. Participants were 
then asked to remain seated for a 15-minute period post-breakfast consumption prior to 
commencing the exercise protocol.  
Once the participant was seated on the ergometer, a small (2ml) blood sample 
was drawn from the cannula, and a heart rate monitor was attached to the participant to 
collect heart rate data throughout the exercise period. A finger prick glucose 
measurement was also completed to ensure that participants were within the guideline 
glucose values (5-11.9mmol/L) prior to commencing exercise and to identify any 
participants who may have required consumption of further carbohydrates and/or to 
adjust their rate of insulin administration based on the finger prick glucose concentration. 
Based on the results of the immediate pre-exercise finger prick glucose measurement, 
participants were asked to provide details of any adjustments to their basal insulin 
regimen ahead of commencing the exercise period. The participants were requested to 
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replicate the selected basal/bolus exercise regimen as closely as possible during 
subsequent experimental trials.  
The exercise protocol completed during both experimental trials was identical to 
the familiarisation session, with increased venous blood and interstitial glucose sampling 
frequency. The participant’s interstitial glucose concentration was measured using the 
FreeStyle Libre™ flash interstitial glucose monitor every 5 minutes. Furthermore, online 
expired gas analysis was completed for 2 minutes at 15 minute intervals, while small 
(2ml) blood samples were drawn from the cannula every 15 minutes. Throughout the 
exercise period, a carbohydrate-rich energy bar (Go-Energy Bar™; Science in Sport) was 
available to be consumed by any participant who was trending towards hypoglycaemic 
glucose concentrations. During the control experimental trial, participant’s estimated 
fluid losses induced through exercise were offset with water provided in three equal 
aliquots at 15 minute intervals during the 60 minute exercise period. During the 
progressive dehydration trial, participants were fully fluid-restricted throughout the 
exercise period.  
In accordance with research previously conducted by Bussau et al (2009) to 
prevent an immediate decline in post-exercise glucose concentrations, participants were 
asked to complete a 10 second maximal effort sprint during the final 10 seconds of the 
exercise protocol. All blood samples and interstitial glucose measurements, coupled with 
final expired gas analysis, were completed prior to beginning the sprint during the final 
seconds of the exercise period. The participants also provided details of any additional 
short-acting insulin bolus administered during the exercise period to counteract 
hyperglycaemia where relevant. Furthermore, any carbohydrates consumed during 
exercise to prevent hypoglycaemia were also noted by the investigators. Once the 
participants had completed the exercise, their heart rate monitor was removed and they 
fully voided their bladder into the pot provided, from which an aliquot was retained for 
subsequent analysis. Participants were then asked to remove all saturated clothing and 
towel dry, before a post-exercise near-nude body mass was obtained.  
 Participants remained within the laboratory for a further 2 hour post-exercise 
recovery period after the completion of the exercise protocol, where short term post-
exercise glycaemic control was assessed. During this time, participants were encouraged 
to remain seated/supine throughout due to postural changes altering fluid composition 
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in the body. During the control trial alone, participants were provided with a bolus of 
fluids (380ml still water) to be consumed within 5 minutes of commencing the post-
exercise recovery period, with no other fluids provided thereafter for the remainder of 
the trial. In contrast, participants remained fully fluid-restricted throughout the post-
exercise recovery period of the dehydration trial. Venous blood samples were collected 
at 15 minute intervals during the first hour of the post-exercise recovery period, with a 
final blood sample obtained at 120 minutes post-exercise. Interstitial glucose 
concentrations were monitored throughout the post-exercise period using the FreeStyle 
Libre™ flash interstitial glucose monitor at 5 minute intervals across the entire 120 
minutes. Participants were also required to void their bladder at 1 hour and 2 hours post-
exercise for subsequent analysis of the urine aliquots retained from each sample 
provided. As with the exercise period, information was recorded for any insulin 
administered or carbohydrates consumed during this post-exercise recovery period 
based on the correction of the interstitial glucose responses to each 
intervention/experimental trial.  
 Following the collection of the final venous blood sample and interstitial glucose 
measurement, the cannula was removed from the participant’s arm and a final finger 
prick capillary glucose measurement was obtained. Based on the DVLA’s regulations 
regarding necessary blood glucose concentration prior to operating a vehicle (DVLA, 
2019), coupled with the aim to prevent any incidences of hypoglycaemia immediately 
following the culmination of the trial, participants were not authorized to immediately 
leave the laboratory. A final capillary blood glucose sample was obtained via finger prick, 
where participants were only cleared to leave the laboratory if they exceeded a blood 
glucose concentration of 5mmol/L, did not present any symptoms of hypoglycaemia and 
were not trending towards hypoglycaemic concentrations based on the direction of the 
FreeStyle Libre™ display arrow. Participants voided their bladder into the pot provided 
before a final near-nude post-trial body mass measurement was obtained. All 
participants were then provided with a morning urine sample collection pot and 48 hour 
post-trial insulin dosing and carbohydrate diary to be completed and returned to the 
investigator prior to the remaining experimental trial.  
 An estimation of the effect of varying hydration status on longer-term glycaemic 
control following each experimental trial was completed using the aforementioned 
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insulin and carbohydrate diary, coupled with the continuous collation of the interstitial 
glucose concentration data, during the initial 48 hours post-trial. The participants were 
required to complete finger prick capillary glucose tests at each significant mealtime at 
the minimum (breakfast, lunch, dinner), along with recording any insulin administered or 
estimated quantity of carbohydrate consumed at any point between meals during the 
post-trial period. Having completed one experimental trial, participants were then asked 
to return 2 days prior to their next experimental trial to have a new flash interstitial 
glucose monitor fitted to the opposite arm. Removal of the final interstitial glucose 
monitor up to 5 days following the final experimental trial signaled the culmination of the 
individual’s participation in the study. A schematic of the full trial day protocol is shown 
in Figure 3.
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Figure 3: Example experimental trial and sampling timeline during the progressive dehydration and euhydration (control) trials. 
Sample every 5 minutes
-45 mins
Arrival
120 mins-20 
mins
Exercising for 60 minutes at ~60% Peak Power 
as  determined via V02max test
60 mins0 mins 15 mins                                 30 mins 45 mins                         60 mins    0 mins-5 mins
2hr follow-up period
Blood sample obtained
FreeStyle Libre scan
2 mins expired gas analysis
380ml Water (Control trial ONLY)
Urine sample collection
Water provision (Control trial ONLY)
Sample every 15 minutes
Standardized breakfast
Start of 60 minutes exercise 
period
Sample every 5 minutes
Sample every 15 minutes
Provided every 15 minutes
(-30 mins)
Cannulation
O2
O2 O2
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Sample Analysis 
The total sample volume for each urine sample was measured by weighing 
imminently upon provision using electronic scales (to the nearest 1g), before a 2ml 
aliquot was retained within individually-allocated storage tubes. The urine mass was 
calculated by subtracting the weight of the individual urine pots (calculated pre-trial) 
from the total urine volume excreted, with each pot rinsed and dried thoroughly to 
ensure there was no cross-contamination of urine samples, thus affecting urine 
osmolality values. Urine osmolality was assessed using the freezing-point depression 
method (Löser Osmometer, Germany) and was completed in duplicate measurements. 
The aliquots of all urine samples collected throughout each experimental trial were 
retained and stored at 3C for subsequent analysis of urine osmolality within 24 hours of 
sample provision.  
During the exercise and post-exercise periods, all venous blood samples collected 
were also used for the determination of venous (whole blood) glucose concentrations. 
Once the blood sample was stored within a hemo-repellent serum collection tube 
following withdrawal from the cannula, immediately a micropipette was utilized to 
withdraw duplicate 100l aliquots from the blood sample prior to clotting. The aliquots of 
venous whole blood were added to an eppendorff containing 1ml of 0.4M perchloric acid 
solution (1:10 dilution), which itself was partially submerged in an ice bath. The 
eppendorff was mixed vigorously before being placed within the ice bath, where the 
perchloric acid negated any ongoing chemical reactions in the blood sample drawn. At 
the culmination of each experimental trial, each sample was placed into the micro-
centrifuge at 12,500 x g for 5 mins at 4C to allow separation of the whole blood pellet 
from the PCA solution, before the samples were stored at -80C for future analysis. Once 
thawed, a quantity of each sample was dispensed into an eppendorff in equal measures, 
before the solutions were vortexed and aliquoted into allocated sample tubes (200l 
samples). Glucose Oxidase reagent kits were utilized in conjunction with the inbuilt iLab 
Aries biochemical (IL, USA) analysis software to determine estimated whole blood 
glucose concentration using a diagnostic assay.  
With each venous whole blood sample drawn from the cannula, the blood sample 
collected into the serum collection tube was allowed to clot at room temperature for 2 
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hours prior to centrifugation. Each blood sample collected was centrifuged at 3500rpm 
for 15 minutes at 4C. Following centrifugation and separation of each whole blood 
component, the maximal portion of serum from each sample was dispensed into a 
separate eppendorff for subsequent analysis of the various hormone concentrations. The 
samples were stored at -80C until analysis was undertaken. Serum cortisol and glucagon 
concentrations were each analyzed using a competitive immunoassay ELISA (Enzo Life 
Sciences, UK), with samples thawed and then centrifuged at 12.5 x g for 3 minutes at 5C. 
Each serum sample was measured in duplicate, with the standard curves produced for 
each plate allowing for the determination of the respective absolute hormone 
concentrations using graphical software (GraphPad Prism Version 7; GraphPad Software, 
California, USA). The determination of copeptin concentrations was completed using a 
specific sandwich immunoluminometric assay on a BRAHMS Kryptor analyzer (Thermo 
Scientific, Germany) as previously described by Fenske et al (2009). The copeptin analysis 
was conducted in the laboratory of Prof. Olle Melander (Lund University, Sweden) by 
their technical support team.  
All online expired breath-by-breath analysis was completed using the OxyCon Pro 
software for the collection of both oxygen consumption (VO2) and carbon dioxide 
production (CO2) data, coupled with estimated respiratory exchange ratio (RER) data. 
Following each experimental trial, it was possible to determine estimated rates of 
carbohydrate and fat oxidation during the exercise period using the equations of 
Jeukendrup and Wallis (2004) denoted for moderate-high intensity (50-75% VO2max) 
exercise: 
Carbohydrate oxidation (g/min): (4.21 x VCO2) – (2.962 x VO2) – (0.4 x n)  
Fat oxidation (g/min): (1.695 x VO2) – (1.701 x VCO2) – (1.77 x n)  
where n is estimated nitrogen content, which is considered to be negligible.  
 
The insulin analogues administered by each participant during the study were 
either humilin, insulin glargine, insulin aspart or determir. Research has identified that 
commercially-available ELISA kits for the determination of insulin concentrations within 
whole blood are not sensitive to a variety of different insulin analogues commonly 
prescribed to diabetic patients (Parfitt et al, 2015). This includes the analogues insulin 
determir and insulin aspart administered by selected participants in this study. As a 
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result, insulin data were expressed as the estimated total units administered using the 
individual basal rates provided. Details of any additional insulin administered during each 
experimental trial and the 48 hour post-trial insulin diary notes were included. Insulin 
data are calculated based on the total units administered up to 8 hours prior to each 
experimental trial, total insulin units administered within-trial, and total post-trial insulin 
administration over a 24 and 48 hour period. Total carbohydrate intake over the 48 hour 
period following each trial was calculated using the relevant nutritional information 
provided and the quantity consumed in the diet, and was detailed in the post-trial diary. 
Additional insulin and carbohydrate requirements for the correction of hypoglycaemia or 
hyperglycaemia were also included in any total insulin and carbohydrate counts. 
 
Statistical Analysis  
FreeStyle Libre™ data has been expressed as both absolute interstitial glucose 
concentrations, and as the mean change from baseline (either ~30 mins pre-exercise or 
60 mins of exercise value) during both the exercise period and the post-exercise recovery 
period, respectively.  
To determine whether the participants were in a similarly hydrated status prior to 
beginning each of the main experimental trials, there was a paired T-test conducted on 
pre-trial body mass and morning urine osmolality between trials. Furthermore, the 
changes in body mass between trials following exercise and at the culmination of each 
experimental trial, were compared to the previous body mass measurement or initial 
body mass measurement via paired T-tests. The primary outcome variables measured 
during exercise and the 2 hour post-exercise recovery period, including interstitial 
glucose and blood glucose responses, urinary variables, endocrine responses (cortisol, 
copeptin and glucagon respectively) and physiological variables including heart rate and 
substrate oxidation, were analyzed using a two-way repeated measures ANOVA. Further 
post-hoc analysis with Bonferroni corrections was undertaken if a significant main effect 
(trial, time and time by trial) was observed for any of the outcome variables. A one-way 
ANOVA was also completed to compare the mean changes in interstitial glucose 
concentrations from baseline during exercise and at hourly intervals during the post-
exercise recovery period between trials. Multiple paired T-tests, with appropriate 
adjustment of statistical significance based on the number of T-tests undertaken, was 
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also utilized to assess whether there were any differences in the average hourly 
interstitial and blood glucose concentrations between trials during exercise and the post-
exercise period respectively. Analysis of the collated interstitial glucose data to assess the 
acute glycaemic response over subsequent days following each experimental trial was 
completed with a two-tailed T-test for the prevalence of stratified glucose concentration 
ranges- hypoglycaemia, euglycaemia, mild hyperglycaemia and severe hyperglycaemia. 
Finally, an assessment of any potential differences between trials regarding total insulin 
administration and carbohydrate intake over the initial 24 and 48hours following the 
experimental trials was completed with respective two-sided T tests. 
 All statistical analysis was completed using IBM SPSS statistics version 26, with 
statistical significance accepted as p<0.05. All data were only considered to be 
significantly different if p<0.05, or lower, with the additional Bonferroni correction 
adjustment on each variable. Data are presented as Mean ± Standard error of the mean 
(SEM) within text and in figures, with the data in tables being presented as Mean ± 
Standard deviation (SD). All graphical content was completed using GraphPad Prism 
Version 7 software. 
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Results 
Participant Characteristics 
Of the 11 participants initially recruited, only 9 participants fully completed all 
experimental trials and procedures associated with the study. One participant dropped 
out of the remainder of the study for personal reasons following the completion of the 
VO2max test, and as such their results are not included in the overall study findings. 
Furthermore, one participant was subsequently removed from the analysis at the 
culmination of the study due to beginning administration of concomitant medication 
halfway through the trials. The form of concomitant medication is believed to negatively 
impact upon glycaemic control (data shown in Appendix 1), as previously reported by 
Sawka et al (2001), Derijks et al (2008) and Knol et al (2008). The n=9 participants mean 
physical characteristics and results from the diabetes self-management questionnaire 
(DSMQ) are detailed in Table 1. 
 
Table 1: Participant (n=9) physical characteristics and diabetes self-management data 
obtained prior to, and following the completion of the initial maximal aerobic capacity 
(VO2max) test. All data presented as Mean  SD. 
 
 
Trial Day Responses 
Hydration Status 
Upon arrival at the laboratory prior to each experimental trial, the participants 
mean initial body mass was not different between trials (P=0.16, Table 2). There was also 
no significant difference in the osmolality of the first morning urine sample aliquots prior 
to each experimental trial (P=0.13, Figure 4), where the mean urine osmolality was 588  
151 mOsm/kg. Taken together, these results indicate that the participants were of a 
similar hydration status prior to beginning each experimental trial.  
Following the completion of the exercise protocol, there was a statistically 
significant difference in post-exercise body mass between trials (p<0.01, Table 2). During 
Age (y):  37.9 ± 3.2  
Height (m): 1.74 ± 0.29 
Body mass (kg): 74.7 ± 3.1 
Duration of T1DM diagnosis (y): 15 ± 2  
DSMQ score: 34 ± 1 
VO2max (ml/kg/min): 46.2 ± 2.6 
60% max exercise workload (W): 142 ± 11 
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the dehydration trial, the mean absolute body mass loss induced with exercise was –0.8  
0.6kg, leading to a mean post-exercise body mass of 73.8  3.1kg. There was a 
statistically significant difference between the post-exercise and pre-exercise body mass 
measurements during the dehydration trial (p<0.01). In contrast, there was only a 
minimal mean body mass loss (–0.1  0.4kg) induced during the exercise period of the 
control trial, and subsequently there was no significant difference in post-exercise body 
mass (74.6 ± 3.2kg) compared to the pre-exercise body mass (p=0.30, Table 2). During the 
post-exercise recovery period of the dehydration trial, the sustained fluid restriction 
protocol led to a further -0.2 ± 0.3kg mean body mass loss from the post-exercise body 
mass. There was a statistically significant difference between the post-trial body mass 
(73.6 ± 3.1kg) and both the initial pre-exercise body mass (p<0.01) and the post-exercise 
body mass measurements (p<0.01; Table 2) during the dehydration trial. Following the 
control trial post-exercise recovery period, the participants lost on average -0.2 ± 0.3kg, 
but there remained no significant difference between the post-trial body mass (74.4 ± 
3.2kg) and either of the previous body mass measurements. The mean absolute body 
mass loss from the respective post-exercise body mass measurements was not 
significantly different between trials (p=0.30). However, there was a statistically 
significant difference in post-trial body mass between trials (p<0.01), while the mean % 
total body mass loss from the respective pre-exercise body mass measurements was also 
significantly different between trials (p<0.01, Table 2).  
There was a statistically significant main effect of trial alone (p<0.01) on the urine 
osmolality responses over time, coupled with a statistically significant time by trial 
interaction (p<0.01, Figure 4). There was a linear increase in urine osmolality over time 
during the dehydration trial, resulting in a statistically significant difference between the 
initial urine sample (AM) osmolality and urine sample osmolality obtained at 1 hour 
(p=0.35) and 2 hours post-exercise (p<0.01) during the dehydration trial. The linear 
decrease in urine sample osmolality over time during the post-exercise recovery period 
of the control trial also resulted in a significant difference between the initial sample 
osmolality and the 2 hour post-exercise value (p<0.01). Following the clear divergence in 
urine osmolality response between trials throughout the post-exercise recovery period 
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post-hoc analysis showed that the mean difference between trials at 2 hours post-
exercise (309  63mOsm/kg) was statistically significant (p<0.01).  
There was a statistically significant effect of both time (p<0.01) and trial (p=0.01) 
on post-exercise cumulative urine output, along with a significant time by trial interaction 
(p<0.01, Figure 5). Post-hoc analysis showed that across both the control and 
dehydration trials, there was a statistically significant difference between the cumulative 
urine output at the beginning of the post-exercise period (0 hours) and at 2 hours post-
exercise (both trials, p<0.01). Furthermore, at 2 hours post-exercise, there was a 
significant difference between the mean cumulative urine output during the control trial 
(538  96g) compared to the corresponding value during the dehydration trial (143  19g, 
p<0.01).  
 
Table 2: Participant body mass measurements obtained prior to (Pre-Trial Body Mass) 
and during each experimental trial (Post-Exercise, Post-Trial). The % total body mass loss 
is calculated as the overall change from Pre-Trial to Post-Trial body mass corrected for 
the total volume of fluid consumed. All body mass measurements recorded in near-nude 
state and to the nearest 0.1kg. All data presented as Mean  SD. Significance accepted at 
p<0.05. 
 
1 significant difference from initial body mass measurement 
2 significant difference from previous body mass measurement 
* significant difference compared to Control trial  
 
 
 Control Dehydration 
Pre-Trial Body Mass (kg) 74.7  9.5 74.4  9.3 
Post-Exercise Body Mass (kg) 74.6  9.5 73.8  9.21,* 
Post-Trial Body Mass (kg) 74.4  9.7 73.6  9.21,2,* 
% Total Body Mass Loss -0.4  0.5 -1.1  0.4* 
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Figure 4: 
Urine osmolality of the initial sample provided upon awakening (AM), at the culmination 
of the 60 minute exercise period (0hrs) and at each hourly interval during the post-
exercise recovery period, following either the full replacement of fluid losses (Control) or 
with total fluid restriction to induce a progressive dehydration (Dehydration). Data 
presented as Mean ± SEM, with statistical significance accepted at p<0.05. Difference 
between trials indicated as *, difference from initial (AM) value indicated by . 
 
 
 
 
Figure 5: Cumulative Urine Mass over the 60 minute exercise period (0hrs) and each hour 
over the subsequent 2 hour post-exercise recovery period, following either the full 
replacement of fluid losses (Control) or with total fluid restriction to induce a progressive 
dehydration. Data presented as Mean ± SEM, with statistical significance accepted at 
p<0.05. Significant difference between trials indicated as *, with significant differences 
from initial (immediately post-exercise- 0 hours) value indicated by .  
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Within-Trial Glucose Responses 
The interstitial glucose data are presented as the change from the baseline 
interstitial glucose concentrations which, during the exercise period, are calculated from 
the pre-breakfast (~30 minutes pre-exercise) interstitial glucose concentration. There was 
a statistically significant main effect of time (p<0.01) on the interstitial glucose response 
during the exercise period (Figure 6A). The interstitial glucose concentration continued to 
increase from the baseline concentration (Control: 9.8  0.9 mmol/L, Dehydration: 7.0  
0.4 mmol/L) as the exercise period proceeded, until the peak increase in interstitial 
glucose concentration occurred at 25 minutes during both experimental trials (Control: 
+2.1  1 mmol/L, Dehydration: +3.7  0.7 mmol/L). During the remainder of the exercise 
period, the interstitial glucose concentrations continued to decline until returning to 
near-baseline levels at the culmination of exercise during the dehydration trial. In 
contrast, the decline in interstitial glucose concentrations from the peak response during 
the control trial continued until the final interstitial glucose measurement (60 minutes) 
was below the pre-exercise interstitial glucose concentration. The change from the 
baseline interstitial glucose concentration was significantly different at the 5 and 10 
minute time points during exercise compared to the 0 minute (immediately pre-exercise) 
value during the control trial. During the dehydration trial, there was a statistically 
significant difference in the change from baseline interstitial glucose concentration 
between the 0 minute and 10-25 minute timepoints respectively (10, 20 minutes, p<0.05; 
15, 20 minutes, p<0.01), and between the 5 minute and 10-25 minute timepoints 
respectively (all timepoints p<0.05).  
There were no significant differences in the interstitial glucose responses 
throughout the post-exercise recovery period between trials or at any timepoint (Figure 
6A). The baseline interstitial glucose concentration during the post-exercise recovery 
period was denoted as the initial (0 mins) post-exercise interstitial glucose concentrations 
(Control: 8.8  1.2 mmol/L, Dehydration: 7.8  0.8 mmol/L). During the first hour of the 
post-exercise period, the mean interstitial glucose concentration continued to increase 
from the baseline interstitial glucose concentration across both trials, until there 
appeared to be a separation by trial. By the culmination of the post-exercise recovery 
period (2 hours post-exercise), the mean difference in the change in interstitial glucose 
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concentration between trials was 2.3 mmol/L (Control +0.6  1.0mmol/L; Dehydration 
+2.9  1.4 mmol/L), yet this did not reach statistical significance (p=0.11).  
 
During the exercise period of the control experimental trial, the mean interstitial 
glucose concentration was 10.8 ± 1.2mmol/L, which was not significantly different from 
the baseline interstitial glucose concentration (9.7 ± 0.9mmol/L; p=0.47). In contrast, 
there was a statistically significant difference (p<0.01) between the average interstitial 
glucose concentration during the exercise period of the dehydration trial (9.4 ± 
0.7mmol/L) compared to the baseline interstitial glucose value (7.0 ± 0.4mmol/L).  
There was no significant difference between the baseline interstitial glucose 
concentration during the post-exercise period of the control trial (8.7 ± 1.2mmol/L) and 
the average interstitial glucose concentration during the entire (2 hour) post-exercise 
period (9.6 ± 0.9mmol/L; p=0.20). There was also no significant difference when the 
average interstitial glucose concentration was expressed at 1 hour intervals in 
comparison to the baseline concentration (1st hour: 9.5 ± 0.9mmol, p=0.71; 2nd hour: 9.7 
± 1.1mmol/L, p=0.79).  
During the post-exercise period of the dehydration trial, there was a statistically 
significant difference between the baseline interstitial glucose concentration (7.8 ± 
0.8mmol/L) and the average interstitial glucose concentration during the entire post-
exercise period (9.8 ± 0.7mmol/L; p=0.02). When the average post-exercise interstitial 
glucose data were expressed at hourly intervals, there were no statistically significant 
differences between the average baseline glucose concentration and both the 1st (8.8 ± 
0.7mmol/L, p=0.09) and 2nd hour (10.7 ± 1.0mmol/L, p=0.07) average interstitial glucose 
concentrations post-exercise. 
 
The blood glucose data are presented as the change from the baseline blood 
glucose concentrations which, during the exercise period, is denoted as the pre-breakfast 
(~30 minutes pre-exercise) blood glucose concentration. As with the changes in 
interstitial glucose concentration during exercise, there was a statistically significant 
effect of time alone on blood glucose responses during exercise (p<0.05; Figure 6B). The 
baseline blood glucose concentrations were 8.8 ± 0.8mmol/L for the control trial and 5.7 
± 0.3mmol/L for the dehydration trial respectively. Upon reaching the peak increase in 
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blood glucose concentrations 15 minutes into the exercise period of both trials (Control 
+1.7  0.7 mmol/L, Dehydration +2.2  0.5 mmol/L), the pattern of change in blood 
glucose concentrations was concurrent with that of the interstitial glucose 
concentrations. There was a steady decline in blood glucose concentrations towards the 
baseline (pre-breakfast) glucose concentrations during both trials, with the final blood 
glucose concentration declining below the baseline blood glucose concentration 
following the culmination of exercise in the control trial only. There was a statistically 
significant difference between the change in blood glucose concentrations during 
exercise at the 15 minutes and 60 minute timepoints (p<0.05), with significant 
differences also evident between the 30 minute and 45 minute and 60 minute timepoints 
respectively (both timepoints, p<0.05). 
There was no significant difference in the mean changes in blood glucose 
concentrations from baseline concentrations between each trial over the duration of the 
post-exercise recovery period (Figure 6B). The baseline blood glucose concentration 
during the post-exercise recovery period was denoted as the initial (0 mins) post-exercise 
blood glucose concentration (Control: 7.8  1.0 mmol/L, Dehydration: 6.0  0.6 mmol/L). 
In a similar manner to that of interstitial glucose responses, blood glucose concentrations 
during the dehydration trial continued to increase throughout the recovery period, even 
with the change in blood glucose from baseline values plateauing at 60 minutes post-
exercise during the control trial (+1.7 ± 0.6mmol/L). At the culmination of the 2 hour 
recovery period, the mean difference in blood glucose responses was consistent with the 
interstitial glucose pattern previously described (Control: +1.2  0.8mmol/L, Dehydration: 
+3.3  1.2mmol/L), which also did not reach statistical significance (p=0.11).  
 
Analysis of the changes in interstitial glucose concentration in comparison to the 
changes in blood glucose concentration were separated by each experimental trial and by 
the exercise and post-exercise recovery periods respectively. There was a statistically 
significant time by type interaction (p<0.05) highlighted during the exercise period of the 
control experimental trial (Figure 7A). There was a significantly different change from the 
baseline interstitial glucose concentration between the 0 and 15 minute timepoints 
(p<0.05), along with the 45 and 60 minute timepoints (p<0.05). In contrast, there was a 
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statistically significant main effect of both time (p<0.01) and type (p<0.05), coupled with 
a significant time by type interaction (p<0.01) for the changes in blood and interstitial 
glucose concentration from the respective baseline concentrations during the exercise 
period of the dehydration trial (Figure 7B). The mean difference between the change in 
interstitial glucose concentration and changes in blood glucose concentration was 0.8 ± 
0.1 mmol/L over the duration of exercise within the dehydration trial. The change in 
interstitial glucose concentrations during exercise was significantly different between the 
0 and 15 minute timepoints (p<0.01) and the 30 minute and 60 minute timepoints 
(p<0.05) respectively. Analysis of the changes in blood glucose concentrations from 
baseline showed there were statistically significant differences between the 15 and 60 
minute timepoints (p<0.05) and between the 30 minute and both the 45 and 60 minute 
timepoints respectively (both timepoints p<0.05). Furthermore, during the dehydration 
trial only, post-hoc analysis highlighted a statistically significant difference between the 
interstitial glucose and blood glucose concentrations at the 15 minute (p<0.01) and 45 
minute (p<0.01) timepoints during exercise. During the entirety of the post-exercise 
recovery period, there were no significant differences between the type of glucose 
measurement (interstitial or blood glucose), or an effect of time on the changes in either 
interstitial or blood glucose concentrations.  
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Figure 6: Changes in the (A) interstitial glucose concentrations and (B) blood glucose concentrations during exercise and throughout the 
post-exercise recovery period of both the control and dehydration trials respectively. Interstitial glucose concentration was measured at 5 
minute intervals throughout each experimental trial, with blood glucose measurements obtained every 15 minutes during exercise and the 
first hour of recovery. During exercise, the baseline (resting) value (R) was taken as the pre-breakfast glucose concentration. Initial post-
exercise (0 mins post-exercise) glucose value was then considered to be the baseline concentration for the calculation of changes in glucose 
concentration during the post-exercise recovery period. All data presented as Mean ± SEM, with statistical significance accepted at p<0.05. 
Significant differences compared to the 0 minute value indicated as , significantly different compared to the 5 minute value indicated by  
in 6(A).  denotes significantly different from 15 minute value,  denotes significantly different from 30 minute value in 6(B).  
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Figure 7: Changes in interstitial glucose concentration and blood glucose concentration during exercise and throughout the post-exercise 
recovery period of the A) control trial and B) progressive dehydration trial. Interstitial glucose was sampled at 5 minute intervals throughout 
each experimental trial, with blood glucose measurements obtained every 15 minutes during exercise and the first hour of recovery. During 
exercise, the baseline (resting) value (R) was taken as the pre-breakfast glucose concentration. Initial post-exercise (0 mins post-exercise) 
glucose value was then considered to be the baseline concentration for the calculation of changes in glucose concentration during the post-
exercise recovery period. All data presented as Mean ± SEM, with significance accepted at p<0.05. Significant difference between trials 
indicated as *, with a significant difference compared to the baseline (R) value indicated by . 
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Endocrine Responses 
Analysis of serum copeptin concentrations throughout each trial reveal a 
statistically significant main effect of both trial (p<0.01) and time (p<0.01), along with a 
significant time by trial interaction (p<0.01, Figure 8). There were no significant 
differences between either the baseline (pre-breakfast) or immediately pre-exercise 
copeptin concentrations between trials. However, during the dehydration trial, there was 
a measurably greater copeptin response following the total fluid restriction protocol 
employed during the completion of the exercise period. Subsequently, there was a 
statistically increased copeptin concentration immediately post-exercise (0 hours, 
p<0.01) compared to pre-breakfast (baseline) values during the dehydration trial only, 
where the mean difference was 25.98 ± 18.53 pmol/L. The copeptin concentration 
remained elevated above baseline concentrations throughout the post-exercise period of 
the dehydration trial with continued fluid restriction, with a statistically significant 
difference between the baseline and 2 hour post-exercise copeptin concentrations 
(p<0.01). There were statistically significant differences in the serum copeptin 
concentrations immediately post-exercise and at 2 hours post-exercise between trials 
(both timepoints, p<0.01).  
The results of the cortisol assay show that there was a statistically significant main 
effect of trial (p<0.01) on serum cortisol concentrations (Figure 9). The mean difference 
in cortisol concentrations between the trials was 6290 ± 610 pg/ml. From baseline (pre-
exercise) values, the mean cortisol concentration increased following the exercise period 
during the dehydration trial until peaking at 30 minutes post-exercise (40690 ± 8760 
pg/ml). In comparison to the control trial, the mean cortisol concentration remained 
elevated throughout the post-exercise recovery period of the dehydration trial, before 
returning towards pre-baseline values at the culmination of the experimental trials. There 
was a statistically significant difference between the mean cortisol concentrations at 1 
hour post-exercise(p<0.01) and 2 hours post-exercise (p=0.03) respectively, compared to 
the 30 minute post-exercise value. The serum cortisol concentrations at 30 minutes post-
exercise were significantly different between trials (p<0.01) and remained elevated above 
the baseline concentration during the dehydration trial until the culmination of the post-
exercise period (2 hours post-exercise).  
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There was also a significant main effect of both time (p<0.01) and trial (p<0.01) on 
serum glucagon concentrations during and following exercise, coupled with a significant 
time by trial interaction (p<0.01, Figure 10). The baseline glucagon concentrations (pre-
breakfast) were significantly different between trials (p<0.01), where the mean 
concentration was 6.75 ± 3.01 pg/ml prior to the control trial, and 4.07 ± 3.10 pg/ml pre-
dehydration trial. During exercise and the subsequent post-exercise recovery period, 
glucagon concentrations did not greatly fluctuate throughout both experimental trials. 
There was a slight decline in serum glucagon concentration from baseline values until 2 
hours post-exercise during the control trial. In contrast, glucagon concentrations 
remained around the baseline concentrations until the culmination of the dehydration 
trial. 
 
  
 
 
Figure 8: Copeptin concentrations by trial, determined from blood samples obtained prior 
to commencing exercise and throughout the post-exercise recovery period. Baseline 
copeptin concentrations taken as the pre-breakfast (approximately 30 minutes pre-
exercise) concentration. All data presented as Mean ± SEM, with statistical significance 
accepted at p<0.05. Any significant difference between trials indicated as *, significant 
difference from baseline value indicated by . 
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Figure 9: Cortisol concentrations by trial, determined from blood samples obtained 
throughout the post-exercise recovery period. Baseline cortisol concentration taken as 
the pre-breakfast concentration. All data presented as Mean ± SEM, with statistical 
significance accepted at p<0.05. Any significant differences between trials indicated as *, 
significant difference from 30 minute post-exercise value indicated by . 
 
 
 
 
 
 
Figure 10: Glucagon concentrations by trial, determined from blood samples obtained 
prior to commencing exercise and throughout the post-exercise recovery period. Baseline 
glucagon concentrations taken as the pre-breakfast concentration. All data presented as 
Mean ± SEM, with statistical significance accepted at p<0.05. Any significant difference 
between trials indicated as *. 
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Post-Trial Glucose Data 
Analysis of all interstitial glucose data collated over the 48 hour period following 
each experimental trial highlighted statistically significant differences in the % of total 
interstitial glucose data points within the defined glycaemic ranges. There was a 
statistically significant increased prevalence of mild hyperglycaemia (7-11mmol/L) in the 
24 hour period following the control experimental trial (p<0.01, Figure 11A), compared to 
post-dehydration trial. Although there appeared to be a greatly increased prevalence of 
euglycaemic interstitial glucose values (4-7mmol/L) during the 24 hours following the 
dehydration trial, there was no statistically significant difference compared to the 24 
hour period post-control trial (p=0.051). Analysis of the entire 48 hour period following 
the respective experimental trials highlighted that there was a continued significantly 
increased prevalence of mild hyperglycaemia (p<0.01) following the control experimental 
trial (Figure 11B), compared to the 48 hour period post-dehydration trial. Overall, the 
majority of the total interstitial glucose concentrations sampled during the entire 48 hour 
period post-trial were within a hyperglycaemic concentration range following both 
experimental trials (Control: 64  20%; Dehydration: 58  21%), however less than 5% 
were within a hypoglycaemic range following the respective experimental trials.  
Analysis of the 48 hour post-trial average interstitial glucose concentration was 
completed in four blocks of 12 hours, which included 2 overnight periods (13-24 hours 
and 37-48 hours respectively; Figure 12). Over the total duration of the 48 hour period, 
the average interstitial glucose concentration was higher following the control trial (9.5  
0.2 mmol/L) in comparison to post-dehydration trial (9.0  0.2 mmol/L), which was 
significantly different (p<0.05). However, there were no statistically significant 
differences in the hourly average interstitial glucose concentrations between trials across 
each 12 hour period up to 48 hours post-trial (each 12 hour series, p>0.05). The 
highlighted section of Figure 7 shows a discernible reduction in the average interstitial 
glucose concentration during the first overnight period (13-24 hours post-trial) following 
the dehydration trial (mean concentration 8.0  0.2 mmol/L), which contrasts the 
glycaemic response during the same period following the control trial (mean 
concentration 10.1  0.1 mmol/L). 
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Figure 11: Prevalence of hypoglycaemic, normoglycaemic, mild hyperglycaemic and 
severe hyperglycaemic interstitial glucose concentrations in the A) initial 24 hours 
following each experimental trial and B) up to the initial 48 hours following each 
experimental trial. Each value is expressed as a percentage of the total number of 
interstitial glucose measurements obtained within each glycaemic range during the 
respective timeframes following the experimental trials. All data presented as Mean ± 
SEM. Significance accepted at p<0.05, with significant differences in prevalence of 
respective interstitial glycaemic ranges between trials indicated as *
Control Dehydration
0
10
20
30
40
50
Trial
%
 t
o
ta
l 
L
ib
re
 s
c
a
n
s
% Hypoglycaemia (<4mM)
% Normoglycaemia (4-7.5 mmM)
% Mild Hyperglycaemia (>7.5-11 mM)
% Severe Hyperglycaemia (>11 mM)
*
A
 54 
 
 
Figure 12: Mean interstitial glucose concentration collated over 1 hour intervals during the 48 hours immediately following each 
experimental trial. The shaded area of the graph denotes each overnight period, and the section of the graph highlighted by the black 
outlined box shows the period where the greatest difference between trials was evident (overnight period 12-20 hours post-trial). Each 
arrow indicates the mean timepoint at which a main meal was consumed during the 48 hour period following each experimental trial. Data 
presented as mean values at each timepoint for each experimental trial, with a pooled SEM shown in the top left of the figure.  
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Insulin / Carbohydrate data  
There was no significant difference in the total insulin units administered up to 8 
hours prior to arrival at the laboratory (pre-trial) for each experimental trial (p=0.06, 
Table 3). Furthermore, carbohydrate consumption in the same overnight period pre-trial 
was also not significantly different between the control and dehydration trial (p=0.79).  
Throughout each experimental trial, the mean units of insulin administered was 3.91  
1.6 during the control trial and 3.65  1.21 during the dehydration trial, with no 
significant difference between trials (p=0.23, Table 3). When the data were expressed by 
individual time periods, there was no significant difference between trials for the insulin 
administered with the consumption of the standardized breakfast pre-trial (1.65  0.92 vs 
1.56  0.73; p<0.05), during exercise (0.92  0.38 vs 0.72  0.30; p=0.17) or post-exercise 
(2.26  0.89 vs 2.17  0.74; p=0.63). Although there was no statistically significant 
difference in the total units of insulin administered during exercise, n=2 participants 
required an additional insulin bolus of 0.5 units on average during the control trial only. 
In contrast, n=3 participants required an additional mean insulin bolus of 0.87 units 
during the post-exercise period of the control trial, with n=2 participants requiring an 
additional mean insulin bolus of 0.75 units during the dehydration trial. There was no 
statistically significant difference in the mean amount of carbohydrate consumed during 
the control (47  34) or dehydration trial (30  0; p=0.17). All participants consumed 26g 
of carbohydrate pre-exercise via the standardized breakfast, however participants only 
required further carbohydrate supplementation during the exercise and post-exercise 
periods respectively of the control trial. N=2 participants required an average of 56  29g 
of carbohydrate to combat hypoglycaemia during exercise, while a further n=2 
participants consumed 21  7g of carbohydrate during the post-exercise recovery period 
of the control trial.  
The total units of insulin administered and amount of carbohydrate consumed (g) 
over the duration of each trial (intra-trial) is the sum of insulin administration and 
carbohydrate consumption during the pre-trial, pre-exercise, exercise and post-exercise 
time periods respectively. The mean units of insulin administered by participants was not 
significantly different between trials (p=0.23; Table 3), nor the amount of carbohydrate 
consumed (p=0.24). Participants administered an average of 8.9  1.2 units in total over 
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the entirety of each experimental trial, while participants consumed an average of 49  
7g of carbohydrate per trial.  
In conjunction with the average interstitial glucose concentration data, there 
were no significant differences between trials for the total insulin units administered over 
the first 24 hours post-trial (p=0.78) or between 24-48 hours post-trial (p=0.51) 
respectively (Table 3). Furthermore, there were no significant differences between trials 
in the estimated total carbohydrate consumption in the first 24 hours post-trial (p=0.37) 
or between 24-48 hours post-trial (p=0.55). Participants administered an average of 
80.55 ± 4.31 total units of insulin and consumed an estimated 440 ± 27g of carbohydrate 
in the 48 hours immediately following each experimental trial.  
 
Table 3: Total insulin administration and carbohydrate consumption pre-trial (the 
overnight period up to 8 hours prior to arrival at the laboratory), within trial (intra-trial), 
0-24 hours post-trial and 24-48 hours post-trial, respectively. All insulin data includes 
both basal and bolus dose administration. Intra-trial data were calculated as the sum of 
pre-exercise, during exercise and over the 2 hour post-exercise recovery period. All data 
presented as Mean  SD. 
 Insulin (units) Carbohydrate (g) 
 Control Dehydration Control Dehydration 
Pre-Trial 6.35  3.46 6.79  3.40 23  6 28  15 
Intra-Trial 3.91  1.60 3.65  1.21 47  34 30  0 
0-24 hours 44.6  12.46 43.61  8.06 252  21 247  30 
24-48 hours 36.28  8.62 36.70  5.83 189  23 191  16 
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Within-Trial Variables 
During the exercise protocol, there appeared to be a progressively elevated heart 
rate over the duration of the progressive dehydration trial compared to the control trial, 
whereby the mean difference in heart rate at the culmination of exercise was 13 ± 10 
bpm. However, a statistically significant main effect of time only was evident for heart 
rate during exercise (p<0.01, Figure 13). The repeated measures analysis showed that the 
mean heart rate values at 15, 20, 30, 40, 45 and 50 minutes respectively were all 
significantly different from the heart rate value at 5 minutes (all timepoints, p<0.05) 
during the control trial. During the dehydration trial, there were significant differences 
between heart rate values at 50 and 60 minutes compared to the resting pre-exercise (0 
minutes) value (both timepoints, p<0.01), coupled with significant differences between 
mean heart rates at 15-60 minutes compared to the 5 minute value (all timepoints, 
p<0.05).  
There was a statistically significant main effect of time on the participants’ 
respiratory exchange ratio during the exercise protocol (p<0.01, Table 4). In comparison 
to the respective values at the 15 minute timepoint, there was a statistically significant 
decrease in respiratory ratios at 45 minutes during the dehydration trial (p<0.01) and at 
60 minutes during the control trial (p<0.05). In accordance with the respiratory exchange 
ratio analysis, there was a statistically significant main effect of time alone on both 
carbohydrate (p<0.01) and fat oxidation rates (p<0.01) respectively across the duration of 
the exercise protocol (Table 4). As expected with the mode and duration of exercise 
undertaken, there was an overall progressive decline in the rate of carbohydrate 
oxidation over time, coupled with an increased rate of fat oxidation over time. The 
repeated measures analysis highlighted a statistically significant difference between the 
mean rate of carbohydrate oxidation at 15 and 60 minutes during the control trial 
(p<0.05), where there was also a significantly different rate of fat oxidation evident 
(p<0.01). During the dehydration trial, there was a significant difference between the 
respective 15 minute and 45 minute carbohydrate oxidation rates (p<0.01) and fat 
oxidation rates (p<0.05). 
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Figure 13: Heart rate data by trial, obtained at 5 minute intervals over the duration of 
exercise, where participants were euhydrated (control), or were wholly fluid restricted 
(dehydration) throughout. All data presented as Mean ± SD, with statistical significance 
accepted as p<0.05.  denotes significant difference from the respective 5 minute values 
during the experimental trials. 
 
 
Table 4: Respiratory Exchange Ratios (RER), Carbohydrate (CHO) oxidation rate and Fat 
oxidation rates calculated at 15 minute intervals during the exercise period via online 
expired gas analysis. All data presented as Mean ± SD. 
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 Control Dehydration Control Dehydration Control Dehydration 
15 mins 0.92  0.04 0.92  0.05 2.07  0.73 2.02  0.53 0.26  0.19 0.29  0.18 
30 mins 0.91  0.05 0.89  0.05 2.01  0.72 1.86  0.63 0.32  0.21 0.38  0.18 
45 mins 0.89  0.03 0.88  0.05 1 1.86  0.58 1.73  0.65 1 0.37  0.15 0.43  0.23 1 
60 mins 0.89  0.05 1 0.89  0.05 1.83  0.66 1 1.76  0.77 0.39  0.19 1 0.45  0.25 
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Discussion 
The aim of the present study was to investigate whether an alteration in 
hydration status, mediated by a restriction of fluid intake during and following a period of 
exercise, affected glycaemic control in patients with Type 1 Diabetes Mellitus (T1DM). In 
contrast to the control trial, where participants consumed a sufficient volume of fluid to 
offset exercise-induced fluid losses, the fluid restriction protocol successfully induced 
~1% body mass loss across the duration of the progressive dehydration trial. This degree 
of body mass reduction induced an increase in circulating vasopressin concentration, as 
assessed indirectly by changes in serum copeptin concentration, compared to a 
euhydrated (control) trial. Serum copeptin is considered a valid biological marker of 
vasopressin release (Szinnai et al, 2007).  
This study is the first to our knowledge to assess whether an alteration in 
hydration status could impact upon resting, within-exercise, or post-exercise glycaemic 
responses of patients with T1DM. It is well established that under conditions of reduced 
fluid availability, including the inadequate replacement of extracellular fluid losses 
induced during exercise, serum osmolality is elevated and subsequently stimulates the 
secretion of vasopressin from the posterior pituitary (McConnell et al, 1997; Rotondo et 
al, 2016; Carroll and James, 2019). The primary osmoregulatory function of vasopressin 
has been comprehensively investigated, however only a paucity of research to date has 
investigated the effects of vasopressin on whole-body substrate metabolism and glucose 
control. In vitro research has identified several potential cellular signaling cascades 
stimulated by the release of vasopressin, culminating in an upregulated endocrine 
response- namely elevated serum cortisol and glucagon concentrations (Yibchok-anun et 
al, 2004; Mavani et al, 2015; Carroll and James, 2019). It is unclear whether glycaemic 
control, an indicator of whole-body glucose utilization and a key factor in the successful 
management of T1DM (Kennedy et al, 2012), may be affected by these alterations in 
substrate metabolism mediated via the elevated vasopressin concentration.  
Prior to each experimental trial, there were no significant differences in initial 
body mass measurements, first-morning urine osmolality or serum copeptin 
concentration between trials, highlighting that participants were of a similar baseline 
hydration status. Changes in body mass are consistently utilized to inform guidelines on 
the volume of fluid to be consumed daily and around exercise to offset the negative 
 60 
effects of dehydration on health and performance respectively (Buoite-Stella et al, 2018). 
McConnell et al (1997) previously justified the successful induction of a range of hydrated 
states via the changes in body mass elicited by varied fluid provision protocols during a 
similar moderate intensity continuous exercise protocol. Furthermore, Carroll and James 
(2019) highlight that changes in total body mass are an effective indicator of acute 
alterations in body water content, provided pre-trial conditions are similar between trials. 
Increased pre-exercise and/or exercise-induced extracellular fluid (sweat) losses are 
associated with a decrease in plasma volume and concurrent increase in serum 
osmolality, leading to the secretion of vasopressin (McConnell et al, 1997; Montain et al, 
1997; Melin et al, 2001; Maresh et al, 2004). In the research conducted to date with non-
diabetic subjects only, the greatest change in serum vasopressin concentrations following 
fluid restricted exercise was consistently shown to be directly correlated with the 
greatest body mass loss and subsequently the greatest increase in serum osmolality, 
independent of baseline hydration status (Montain et al, 1997; Maresh et al, 2004).  
The successful induction of a mildly dehydrated state can also be observed via the 
significantly increased urine osmolality and significantly lower cumulative urine mass 
following exercise in the dehydration trial, compared to the control trial. At rest, T1DM 
patients often display a markedly increased urine flow rate and a concomitantly 
decreased urine osmolality compared to healthy subjects (Ahloulay et al, 1999; Bankir et 
al, 2001). Excess plasma glucose stimulates urinary glucose excretion (glycosuria) and 
may lead to prolonged fluid losses, which is symptomatic of untreated T1DM (Bankir et 
al, 2001). However, T1DM patients have been shown to display an upregulated renal 
concentrating ability, where there is increased reabsorption of fluids that would 
otherwise have been excreted with any excess glucose in the urine (Ahloulay et al, 1999). 
This is the only study to date to have assessed urinary responses of T1DM subjects during 
exercise, where the alterations in urine concentrating ability are likely to be influenced by 
fluctuations in vasopressin concentration. These findings compliment previous research 
with non-diabetic subjects, which have shown that the urine flow rate is decreased with 
various degrees of dehydration (increase in plasma osmolality) due to an increased rate 
of renal fluid reabsorption stimulated by increased vasopressin secretion (McConnell et 
al, 1997; Ahloulay et al, 1999; Bankir et al, 2001). Increased fluid conservation in response 
to hypohydration would also be expected to lead to a linear increase in urine osmolality, 
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as observed during the progressive dehydration trial in the current study. Melin et al 
(2001) highlighted that following exercise-induced dehydration, non-diabetic subjects 
displayed an increased urine osmolality in line with an increased vasopressin 
concentration.  
Overall, the data indicate that the fluid restriction protocol employed throughout 
the progressive dehydration trial elicited a significant, negative change in the 
participants’ hydration status, compared to the control experimental trial. Analysis of the 
changes in the selected markers of hydration status (body mass, urine osmolality and 
cumulative urine output) post-exercise and post-trial respectively showed statistically 
significant differences in comparison to pre-trial values during the progressive 
dehydration trial. At the culmination of the post-exercise recovery period, participants in 
the progressive dehydration trial also had a significantly increased body mass loss, 
elevated urine osmolality and reduced cumulative urine output compared to the control 
trial. During the post-exercise recovery period, the serum copeptin concentration was 
also significantly elevated above the time-aligned values for euhydrated subjects. Taken 
together, these results confirm that a mild state of dehydration was successfully induced 
and subsequently stimulated the secretion of vasopressin to promote an increased rate 
of renal fluid reabsorption, aiding the maintenance of intracellular fluid composition 
despite the continued extracellular fluid losses.  
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Vasopressin Physiology and Glycaemic Responses 
Although the relationship between vasopressin, fluid intake and whole-body 
osmoregulation is well established, the increased vasopressin concentration stimulated 
by the progressive dehydration protocol during the current study is also thought to affect 
glucose metabolism. A milieu of endocrine signalling cascades may be stimulated by the 
binding of vasopressin to peripheral sub-receptors, which promote an upregulated rate of 
endogenous glucose production (Koshimizu et al, 2012; Mavani et al, 2015, Muscogiuri et 
al, 2016). Vasopressin has been shown to directly stimulate the release of glucagon from 
the pancreatic islet alpha cells, and both directly and indirectly stimulate the release of 
cortisol from the adrenal gland in vitro (Perraudin et al, 1993; Yibchok-anun et al, 2004; 
Koshimizu et al, 2012). The increase in hepatic glucose production stimulated by the 
secretion of both glucagon and cortisol, combined with the absence of endogenous 
insulin production that characterizes T1DM, may lead to an unimpaired continued rise in 
circulating glucose concentrations (Mavani et al, 2015).  To date, there has been a paucity 
of research which has investigated the cellular signalling pathways linking increased 
vasopressin release in response to fluid restriction or deprivation, and the proposed 
effect on glucose metabolism. Observational studies and longitudinal research with non-
diabetic subjects have shown that differences in habitual fluid intake or chronic 
manipulations of daily fluid intake lead to alterations in long-term glycaemic control and 
affect circulating concentrations of a variety of metabolic hormones (Burge et al, 2001; 
Johnson et al, 2017; Enhorning et al, 2019; Carroll and James, 2019). While no cellular 
markers of endogenous glucose production were measured during the current study, the 
balance of glucose production and disposal was assessed by tracking interstitial and 
blood glucose concentrations during and following a bout of submaximal exercise. There 
was a tendency for an elevated interstitial and blood glucose response during the 
progressive dehydration trial, which is consistent with an upregulated hepatic glucose 
output following vasopressin-mediated stimulation of increased glucagon and/or cortisol 
secretion.  
The results of the current study show that although there was a trend for a 
greater glycaemic response during the dehydration trial, there were no statistically 
significant differences in the change in glucose concentrations between trials during 
exercise or the subsequent post-exercise recovery period. There was a greater peak 
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increase in both blood and interstitial glucose concentrations during the exercise period 
of the progressive dehydration trial, compared to the control trial. Furthermore, blood 
and interstitial glucose concentrations declined from the maximal glycaemic response to 
below the respective baseline glucose concentrations during the control trial only. In 
contrast, mildly dehydrated subjects’ interstitial and blood glucose concentrations 
remained above the respective baseline glucose concentrations throughout exercise. 
During the post-exercise recovery period, there was a continued increase in blood and 
interstitial glucose concentrations from baseline values until the culmination of the 
dehydration trial. The peak interstitial and blood glucose responses during the control 
trial occurred at 60mins post-exercise, before gradually declining towards the respective 
baseline concentrations. The discrepancies in glycaemic control during and following 
exercise may be the result of a vasopressin-mediated increase in endogenous glucose 
production (Cryer, 2012; Mavani et al, 2015; Yostens, 2018). However, despite the 
hypothesized vasopressin-mediated increase in glucagon concentrations and potentially 
upregulated hepatic glucose production, the progressive dehydration protocol did not 
lead to any significant differences in serum glucagon concentrations during or following 
exercise, compared to euhydrated subject values.  
It was anticipated that the increased serum copeptin (vasopressin) concentration 
mediated by the progressive dehydration protocol would stimulate a further increase in 
glucagon secretion via V1b receptor binding and subsequent stimulation of the 
pancreatic islet alpha cells (Koshimizu et al, 2012; Mavani et al, 2015; Muscogiuri et al, 
2016). A series of in vitro studies conducted by Abu-Basha et al (2002) and Yibchok-anun 
et al (2004) previously highlighted a dose-dependent increase in alpha cell glucagon 
secretion with administration of increased physiological doses of vasopressin. Any 
vasopressin-mediated increase in glucagon secretion was thought to transiently impair 
T1DM patients’ glucoregulation due to the absence of endogenous, counterbalancing 
insulin production combined with the glucagon-mediated rise in hepatic glycogenolysis 
and gluconeogenesis (Bankir et al, 2001; Mavani et al, 2015). There was a statistically 
significant difference in baseline (pre-breakfast) serum glucagon concentrations between 
trials. However, thereafter there was no significant difference in pre-exercise or any post-
exercise glucagon concentrations between euhydrated and mildly dehydrated subjects, 
despite the significantly elevated post-exercise copeptin concentrations during the 
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dehydration trial versus euhydrated subject values. The differing baseline glucagon 
concentration between trials did not translate to any significant difference in baseline 
blood or interstitial glucose concentrations between trials. Furthermore, baseline 
glucagon concentrations in each trial did not reach the elevated basal levels previously 
reported by Farhy et al (2012) for T1DM patients under resting, euglycaemic conditions.  
There are several physiological mechanisms that may affect the vasopressin-
mediated glucagon response, and therefore account for the absence of any significant 
differences in glucagon concentrations between euhydrated and mildly dehydrated 
subjects in the current study, independent of the significant changes in vasopressin 
concentrations between trials.  Firstly, the limited in vitro research that has investigated 
the changes in vasopressin-mediated glucagon secretion to date have studied the effects 
of administering a wide vasopressin concentration range (3-300pmol/L) in isolated 
pancreatic alpha cells. The vasopressin concentration threshold that is required to 
stimulate an increase in glucagon secretion from the alpha cells, beyond the reported 
elevated basal vasopressin concentrations associated with T1DM patients, therefore 
remains unclear (Abu-Basha et al, 2002; Yibchok-anun et al, 2004; Koshimizu et al, 2012).  
This is the first study to date to assess changes in vasopressin-mediated glucagon 
secretion in vivo following differing fluid intake regimens. Salehi et al (2006) previously 
postulated that the relationship between glucagon secretion and circulating glucose 
concentrations may be U-shaped in nature, whereby only hypoglycaemia and severely 
hyperglycaemic glucose concentrations can stimulate the maximal glucagon response. 
The underlying intracellular mechanisms that explain this extreme glucose-dependent 
response are unclear, and no research to date has elucidated whether the circulating 
glucose concentrations affect vasopressin-mediated glucagon secretion. However, this 
concept contrasts the impaired glucagon counter-regulatory response to hypoglycaemia 
associated with T1DM (Diedrich et al, 2002; McCrimmon and Sherwin, 2010; Younk et al, 
2011). Glucagon is the primary counter-regulatory hormone, whereby a combination of 
the impaired counter-regulatory neuro-endocrine responses with administration of an 
excessive insulin dose and an impaired awareness of hypoglycaemia symptoms leads to 
an increased risk of hypoglycaemia arising in T1DM patients (Diedrich et al, 2002; 
McCrimmon and Sherwin, 2010; Cryer, 2012; Yosten, 2018). Furthermore, the average 
blood and interstitial glucose responses during exercise and the post-exercise recovery 
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period of both trials of the current study were sufficient to prevent a decline to within a 
hypoglycaemic concentration range (<3.9mmol/L) at any time. The dysfunction of the 
pancreatic alpha cells, and subsequently dysregulated glucagon secretion in response to 
hypoglycaemia, is therefore unlikely to be responsible for the impaired vasopressin-
mediated glucagon response during the dehydration trial. Although there was a trend for 
a greater glycaemic response during the dehydration trial, neither the blood or interstitial 
glucose concentrations rose to severely hyperglycaemic concentrations during either 
experimental trial. Furthermore, the hypothesized increase in glucagon secretion 
associated with severe hyperglycaemia is only applicable to patients who are newly 
diagnosed with T1DM, or T1DM patients with poor glycaemic control, when severe 
hyperglycaemia regularly arises (Yosten , 2018). Further research is required to fully 
elucidate the physiology linking glucagon release and glucose concentrations in T1DM 
patients, including whether the vasopressin-mediated glucagon response may be 
affected. The results of the current study instead align with research conducted by 
Zander et al (1985), which highlighted that the glucagon response during exercise- 
provided there was no immediate threat of hypoglycaemia arising, was maintained 
throughout continuous, moderate intensity exercise. Blood and interstitial glucose 
concentrations tended to remain close to or were elevated beyond the respective 
baseline glucose concentrations during the exercise and post-exercise periods of each 
experimental trial, with no incidences of hypoglycaemia reported throughout the study. 
There was therefore no required glucagon counter-regulatory response during or 
following exercise.  
In contrast to the insignificant differences in vasopressin-mediated glucagon 
concentrations between trials, the results show that there was a significantly elevated 
serum cortisol concentration at 30 minutes of the post-exercise recovery period of the 
dehydration trial, compared to the control trial. Furthermore, serum cortisol 
concentrations during the progressive dehydration trial remained elevated above the 
corresponding values for the euhydrated trial throughout the post-exercise recovery 
period. The current study is one of very few to have investigated the association between 
variable hydration status and either salivary or serum cortisol responses during and 
following exercise. Independent of the mode of exercise completed or method of 
inducing body mass losses (dehydration), cortisol concentrations have generally been 
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shown to be elevated in mildly dehydrated subjects around exercise (Maresh et al, 2006). 
However, Svensden et al (2014) highlighted no significant differences in plasma cortisol 
concentrations between euhydrated and acutely dehydrated (-3.9% body mass loss) non-
diabetic participants following prolonged, low intensity exercise, although there was a 
significant increase in cortisol concentration evident from pre-exercise levels across both 
trials. No research to date has directly investigated how the elevated vasopressin 
concentrations associated with T1DM may affect the cortisol response around exercise.  
Despite the clear physiological link between hydration status (vasopressin 
concentration), whole-body osmoregulation and changes in metabolic hormone 
concentrations, including cortisol, only a few observational or longitudinal studies have 
shown an association between fluid intake, changes in basal cortisol concentration and 
subsequently basal glucose responses (Burge et al, 2001; Johnson et al, 2017; Carroll and 
James, 2019). Separate review papers on the effect of fluid intake on glucoregulation 
have postulated that as ACTH and cortisol secretion via direct stimulation by vasopressin 
is not regulated by the same intrinsic negative feedback mechanism as CRH-induced 
cortisol release, a continuous cycle of increased blood glucose concentrations due to 
persistent vasopressin-mediated cortisol release may be evident with chronic stress, 
which would subsequently increase serum osmolality and impair whole-body 
osmoregulation in T1DM patients (Mavani et al, 2015; Muscogiuri et al, 2016) 
The cellular signalling cascades stimulated by an increase in vasopressin 
concentration that ultimately lead to an increase in adrenal cortisol secretion have been 
comprehensively studied in vitro (Goncharova, 2013). The endogenous secretion and/or 
exogenous administration of graded doses of vasopressin leads to the direct stimulation 
of the V1a receptors located on the adrenal gland, resulting in the dose-dependent 
secretion of cortisol (Perraudin et al, 1993; Goncharova, 2013; Mavani et al, 2015). 
Furthermore, vasopressin binds to the anterior pituitary V1b receptors and augments the 
CRH-mediated release of cortisol via ACTH stimulation, or may directly stimulate pituitary 
ACTH release and subsequently increase adrenal cortisol secretion (Koshimizu et al, 2012; 
Goncharova, 2013; Mavani et al, 2015). Cortisol exerts several short-term and long-term 
effects on whole-body glucose metabolism, which is particularly relevant to T1DM 
patients in the absence of counter-regulatory endogenous insulin production to oppose 
the cortisol-mediated increased rate of glucose appearance. Both transient and 
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chronically elevated cortisol levels have been shown to affect hepatic glucose production 
via gluconeogenesis, epinephrine-mediated skeletal muscle glycogenolysis and peripheral 
insulin sensitivity (Andrews and Walker, 1999; Kuo et al, 2013). Vasopressin is generally 
considered to have a permissive role in the cellular response to acute stress via the 
potentiation of the CRH-mediated increase in ACTH secretion, which leads to an increase 
in cortisol concentration (Goncharova, 2013; Rotondo et al, 2016). In contrast, 
vasopressin-mediated increase in pituitary ACTH secretion, and subsequent adrenal 
cortisol secretion, is solely responsible for the chronic stress response (Kuo et al, 2015; 
Mavani et al, 2015; Rotondo et al, 2016). 
The acute stress response is composed of both non-genomic and transcription-
dependent effects, and may account for the transiently greater glycaemic response 
evident during the dehydration trial of the current study. During the dehydration trial, 
there was a progressive rise in serum cortisol concentrations from baseline until peak 
serum cortisol concentrations arose at 30 minutes post-exercise, before declining to 
baseline (pre-exercise) levels. In contrast, serum cortisol concentrations progressively 
declined from baseline values over the duration of the control experimental trial. The 
progressive increase in both vasopressin (copeptin) concentration and serum cortisol 
concentrations throughout much of the dehydration trial may be indicative of a 
vasopressin-mediated acute stress response to the mild level of dehydration induced 
around exercise. Wiesli et al (2005) previously reported a short-term increase in post-
prandial glucose concentrations due to an increase in salivary cortisol concentration in 
response to acute psychosocial stress. Acute cellular stress responses- independent of 
vasopressin or CRH-mediated ACTH/cortisol secretion, act through non-genomic 
mechanisms to rapidly preserve and increase the circulating glucose concentration in 
conjunction with other counter-regulatory hormones (e.g. epinephrine) in response to a 
novel stress (Kuo et al, 2013). The transient vasopressin-mediated cortisol response to 
the acute osmoregulatory stress during the current study is also supported by the gradual 
increase in copeptin (vasopressin) degradation over time from the peak copeptin 
response, coupled with a short yet statistically significant increase in cortisol secretion 
during the post-exercise period of the dehydration trial. Bussau et al (2006) also reported 
a peak cortisol response up to 30 minutes following the completion of a similar maximal 
sprint activity at the end of continuous, moderate intensity exercise under 
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hyperinsulinemic conditions. It is unclear whether the maximal sprint at the end of 
exercise and mild dehydration may synergistically upregulate the response to acute 
osmoregulatory stress and affect whole-body glucose responses.  
In contrast, despite vasopressin-mediated ACTH (and subsequently cortisol) 
secretion primarily affecting the physiological responses to chronic cellular stress, it is 
unlikely that this type of response is stimulated by a mild osmoregulatory response, such 
as the level of dehydration induced during the current study. Perraudin et al (1993) 
demonstrated that chronically elevated vasopressin concentrations- indicative of a 
chronic stress response, responded in a biphasic manner and led to the eventual 
desensitization of adrenal V1a vasopressin receptors. Although there was a gradual 
decline from the peak cortisol response at 30 minutes post-exercise during the 
dehydration trial of the current study, there appeared to be no plateau in cortisol 
concentrations. It is unclear whether this biphasic response is exclusive to V1a receptor 
mediated increases in cortisol secretion. Furthermore, Aguilera and Rabadan-Diehl (2000) 
have highlighted that only 2% water deprivation from baseline body composition led to a 
decrease in vasopressin-mediated ACTH levels due to decreased pituitary V1b receptor 
expression. It is unclear why there may be discrepancies in the vasopressin-mediated 
response to different levels of osmoregulatory stress, and future research should aim to 
assess pituitary receptor function/expression with varying levels of dehydration. Chronic 
hypercortisolemia arising via repeated vasopressin stimulation often leads to the 
development of chronic hyperglycaemia and insulin resistance. Kuo et al (2015) 
highlighted that prolonged elevations in cortisol concentration stimulated an upregulated 
expression of the key regulatory enzymes in the various tissue-specific pathways that 
regulate glucose metabolism. However, there is an inevitable delay in the prolonged 
metabolic actions of cortisol due to the transcription-dependent effects of the elevated 
cortisol concentrations on the target genes and subsequent protein expression within the 
nucleus. It is therefore reasonable to conclude that the small, transient elevated post-
exercise glycaemic response of mildly dehydrated T1DM patients during the current 
study is an acute response to the mild osmoregulatory stress and is evidence of the short-
term effects of cortisol on glucose metabolism. Although there was continued fluid 
restriction throughout the post-exercise observation period, both vasopressin (copeptin) 
and cortisol concentrations declined from their respective peak responses. The results of 
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the current study contrast with selected review papers that have attempted to assess the 
effect of fluid intake on glucoregulation. Mavani et al (2015) and Moscogiuri et al (2016) 
postulated that as ACTH and cortisol secretion via direct stimulation by vasopressin is not 
regulated by the same intrinsic negative feedback mechanism as CRH-induced cortisol 
release, a continuous cycle of increased blood glucose concentrations due to persistent 
vasopressin-mediated cortisol release may be evident with chronic stress, which would 
subsequently increase serum osmolality and impair whole-body osmoregulation in T1DM 
patients.   
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Substrate Utilization 
The current study is one of very few to detail the fluctuations in substrate 
utilization during exercise completed by T1DM patients. Previous research has 
established that amongst other factors, dysregulated glucose control around exercise 
(Jenni et al, 2008) and the type of exercise completed (Iscoe and Riddell, 2011; Bally, 
2016) are primarily responsible for the effects on whole-body and skeletal muscle 
metabolism of T1DM patients during and following exercise. To date, there has been 
limited research conducted that has evaluated substrate metabolism under variable 
hydrated states, but only in healthy (disease-free) subjects.  
The results of the current study showed no significant difference in substrate 
oxidation between trials as assessed by indirect calorimetry and Respiratory Exchange 
Ratio (RER). The average RER values during the dehydration trial were never higher than 
during the control trial, while the estimated rates of carbohydrate oxidation and fat 
oxidation were not significantly different between trials at any timepoint. Walsh et al 
(1994) and Logan-Sprenger et al (2013) previously highlighted no significant differences in 
RER values at any timepoint between euhydrated subjects and those who were 
dehydrated by up to 3% of pre-exercise body mass during continuous, submaximal 
exercise. Taken together, the results of these studies are in stark contrast with almost all 
previous research, which have consistently shown that male and female participants who 
were partially or wholly fluid restricted during prolonged, submaximal exercise had 
significantly elevated RER values throughout exercise, compared to euhydrated subjects 
(Hargreaves et al, 1996; Gonzalez-Alonso et al, 1999; Logan-Sprenger et al, 2012, 2015).  
Furthermore, research has tended to highlight an increased rate of carbohydrate 
oxidation and concurrently decreased rate of fat oxidation for dehydrated subjects 
throughout continuous exercise, compared to euhydrated subjects. During the current 
study, there was a main effect of time only on the respective substrate oxidation rates 
during both trials, with an increased rate of fat oxidation and concurrent decline in the 
rate of carbohydrate oxidation from the initial 15 minute value, which is consistently 
observed during submaximal, continuous exercise (Fallowfield et al, 1996; Logan-
Sprenger et al, 2012).  
There was a gradual decline in RER values evident during both experimental trials 
of the current study, which is indicative of slight, progressive suppression of carbohydrate 
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oxidation throughout exercise associated with muscle glycogen depletion. However, 
there were no significant differences in the respective substrate oxidation rates or for the 
total amount of carbohydrate or fat oxidised during exercise between trials. The results 
of the current study align with those of Logan-Sprenger et al (2013), who reported no 
difference in RER values, rate of carbohydrate and fat oxidation, or total oxidation of the 
respective substrates between euhydrated and mildly dehydrated males. However, in 
their study they reported a 24% increased rate of intramuscular glycogen utilisation 
across the duration of exercise during the dehydration trial, compared to euhydrated 
subjects. Although an increased rate of skeletal muscle glycogenolysis has been 
consistently reported with varying levels of dehydration across several other studies 
previously, estimated whole-body carbohydrate oxidation has also been shown to be 
concurrently increased under hypohydrated conditions (Hargreaves et al, 1996; Gonzalez-
Alonso et al, 1999; Logan-Sprenger et al, 2012, 2015).  
Although the submaximal exercise protocol during the current study was 
considerably shorter compared to previous research, this itself does not explain the 
discrepancies in substrate utilisation responses. A series of studies by Logan-Sprenger et 
al (2013, 2015) highlighted that up to 60 minutes into an extended submaximal exercise 
protocol, there was an evident trend for increased intramuscular glycogen utilisation 
during the respective dehydration trials.  These results indicate that even at a similarly 
mild level of dehydration induced during the current study (~1% pre-exercise body mass), 
there were significant alterations in substrate metabolism evident at a tissue level.  
Research to date assessing the physiological mechanisms that stimulate the elevated 
skeletal muscle glycogenolysis associated with dehydration has proven equivocal, but it is 
thought that epinephrine secretion or local intramuscular temperature may be 
responsible (Logan-Sprenger et al, 2013). 
It is important to recognise that the assessment of whole-body substrate 
utilisation during exercise; indicated by RER values, does not allow for the measurement 
of tissue-specific differences in substrate utilisation. Wallis and Jeukendrup (2005) stated 
that skeletal muscle metabolism may be accurately reflected in the composition of the 
expired breaths collected during lower intensity exercise, where there is a reduced 
blood/muscle lactate accumulation. However, it is possible that selected modes of 
exercise may lead to systemic RER values inaccurately reflecting skeletal muscle 
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metabolism, due to discrepancies in skeletal muscle recruitment and movement 
efficiency patterns (Hargreaves and Spriet, 2008; Cheneviere et al, 2010). A further 
consideration are the fluctuations in substrate utilisation of non-contracting tissues 
during exercise, which may lead to alterations in RER values (Febbraio et al, 1996). 
However, the active muscle mass during cycle-ergometer based exercise, for example, is 
predominantly lower-body and therefore the whole-body estimates of substrate 
utilization are likely to correlate with skeletal muscle metabolism (Cheneviere et al, 
2010). Jansson (1982) initially showed that the rates of energy consumption at a whole-
body (RER) and isolated skeletal muscle level (RQ) were closely matched during low 
intensity exercise, regardless of the composition of the diet consumed prior to exercise. 
Furthermore, Gonzalez-Alonso et al (1999) showed that estimates of substrate utilisation 
from isolated exercising legs were not significantly different compared to the time-
aligned RER values during prolonged exercise. The whole-body and tissue-level values 
also remained significantly elevated above euhydrated RER and RQ values during 
exercise. RER can therefore be considered as an accurate measurement of substrate 
oxidation rates during cycle-ergometer based exercise, where oxygen cost and substrate 
utilisation is predominantly regulated by the metabolically active tissues of the lower 
body.  
 
 
 
  
 73 
Post-Trial Hypoglycaemia, Hyperglycaemia Prevalence 
It is unclear whether a similar increase in skeletal muscle glycogen utilisation 
compared to Logan-Sprenger et al (2013) study occurred during the exercise period of the 
dehydration trial. The level of dehydration was not as severe during the current study, 
while there was also no measurement of the rate of skeletal muscle (tissue-specific) 
substrate utilization during the current study. No study to date has assessed the 
potentially differing rates of skeletal muscle glycogen resynthesis in T1DM patients 
compared to non-DM patients. There are a number of factors which influence the rate of 
glycogen replenishment, including the increased insulin sensitivity of skeletal muscle that 
arises, particularly following glycogen-depleting exercise (Jensen et al, 2011). The data 
from the current study show a clear divergence in the average interstitial glucose 
concentrations between trials in the hours immediately prior to the initial overnight 
period. However, the mechanisms which may explain the delayed replenishment of 
intramuscular and hepatic glycogen stores up to 12 hours following the culmination of 
the dehydration trial are unclear. It is expected that with sufficient ingestion of 
carbohydrates, glycogen replenishment would occur within 4-6 hours following the 
proposed increased rate of skeletal muscle glycogenolysis during the dehydration trial. 
Despite the short-term elevation in cortisol concentration evident during the post-
exercise recovery period of the dehydration trial compared to euhydrated subjects, there 
is evidence from in vitro research that an increase in cortisol may induce a transient 
skeletal muscle insulin resistance.  
In the only study to date to assess glycaemic responses of T1DM patients to 
alterations in cortisol release, a post-prandial increase in salivary cortisol concentration 
subsequently led to a transient decrease in insulin sensitivity, therefore preventing a 
sudden decline in glucose concentrations (Wiesli et al, 2005).  Glucocorticoid-induced 
insulin resistance in peripheral tissues including skeletal muscle leads to impaired insulin-
mediated glucose uptake (Andrews and Walker, 1999). It was previously thought that 
chronically elevated glucocorticoid concentrations indicative of a variety of metabolic 
disorders were required to stimulate changes in glucose utilization (Rizza et al, 1982). 
However, a short-term increase in glucocorticoid concentration, such as those observed 
during the dehydration trial of the current study, has been shown to suppress peripheral 
tissues’ insulin sensitivity, rather than lead to the development of a chronically insulin 
 74 
resistant state (Andrews and Walker, 1999; Geer et al, 2014). Studies to date have not 
assessed the effect of changes in glucocorticoid concentrations on the intracellular 
glucose metabolism of Diabetes Mellitus patients, which is surprising given the impaired 
insulin sensitivity commonly associated with poorly controlled T1DM (Kennedy et al, 
2013; Riddell et al, 2017). No investigation of potential alterations in insulin signalling 
cascades with fluctuations in serum cortisol concentrations were undertaken during the 
current study. However, elevated glucocorticoid (cortisol) concentrations have been 
shown to impair GLUT4 vesicle translocation to the cell membrane via the Akt/Protein 
Kinase B (PKB) signalling pathway (Figure 14) (Morgan et al, 2009). Overall, the impaired 
translocation of GLUT4 molecules is the result of altered phosphorylation patterns rather 
than changes in signalling molecule expression, as the expression of GLUT4 itself is 
upregulated in the presence of increased local glucocorticoid concentrations (Ruzzin et al, 
2005). However, the impaired GLUT4 translocation is likely to be overwhelmed by the 
exercise-induced increase in GLUT4 translocation following skeletal muscle contraction 
mediated upregulation of AMPK activity (Younk et al, 2011; Riddell et al, 2017). 
Furthermore, research to date has tended to only assess the effects of synthetic 
glucocorticoid administration on insulin sensitivity.  
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Figure 14: Proposed cellular signalling cascades that initially result in an increased 
secretion of adrenal cortisol following direct stimulation by vasopressin binding with 
adrenal V1a receptors, or indirect stimulation of ACTH release by vasopressin binding 
with anterior pituitary V1b receptors. The vasopressin-mediated increase in cortisol 
concentrations is hypothesized to lead to alterations in insulin signalling, leading to 
insulin resistance in peripheral tissues (skeletal muscle). 
 
To date, there has been limited research which has investigated acute post-
exercise/post-trial glycaemic responses and glycaemic excursions in the hours 
immediately following an exercise-based intervention. The focus of such research is often 
directed towards the overnight responses of Type 1 Diabetes Mellitus patients (up to 12 
hours post-exercise), following a manipulation of nutritional or insulin regimens, and 
where the exercise itself is often completed in the evening (Rhabasa-Lloret et al, 2001; 
West et al, 2011; Campbell et al, 2013, Gomez et al, 2015).  Specifically, there is a desire 
to avoid late-night (nocturnal) post-exercise hypoglycaemia, where the aim of previous 
exercise-based strategies has been to stimulate an upregulated neuro-endocrine 
response and preserve or immediately increase blood glucose concentrations. Analysis of 
the collated interstitial glucose concentrations for all participants up to 48 hours post-
trial highlighted an increased prevalence of euglycaemic interstitial glucose concentration 
range (4-7mmol/L) up to 24 hours following the dehydration trial, compared to the 
control trial. Furthermore, there was a significantly decreased prevalence of mild 
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hyperglycaemic (7-11mmol/L) interstitial glucose concentrations up to 24 hours and 48 
hours following the dehydration trial. Based on the average number of total interstitial 
glucose data points (‘scans’) obtained over the 48 hour period following the culmination 
of each experimental trial, discrepancies in glycaemic prevalence can be evaluated 
objectively. For example, the statistically significant 6.7% reduction in the prevalence of 
mild hyperglycaemia up to 48 hours post-dehydration trial equates to a total of 3 hours 
where there is ‘tighter’ glycaemic control, compared to the same timeframe following the 
control trial. Furthermore, although not statistically significant, there was a discernible 
increase in the prevalence of euglycaemic glucose concentrations in the 48 hours 
immediately following the culmination of the dehydration trial (15.5% increase on 
average). It is likely that the large standard deviations associated with this individual 
variable do not equate to statistically significant results. However, due to the decreased 
cumulative prevalence of hyperglycaemic values (‘mild’ and ‘severe’) compared to the 48 
hours post-control trial, this equates to approximately 7 hours of additional time within a 
euglycaemic concentration range. There was no increased threat of hypoglycaemia 
associated with an improved acute glucose profile during the 48 hour period following 
the dehydration trial. Furthermore, the differences in acute glycaemic responses 
following each trial were not the result of any significant differences in the total units of 
insulin administered or total carbohydrate consumed between trials up to 24 hours and 
48 hours following each experimental trial. Although there was no record of daily fluid 
intake for any participant following each trial during the current study, hypohydration has 
been shown to have no effect on skeletal muscle glycogen resynthesis (Neufer et al, 
1991). In the event that T1DM patients remained hypohydrated following the 
culmination of the dehydration trial, it is unlikely that hydration status will account for 
the discrepancies in post-trial hypoglycemia and hyperglycaemia prevalence between 
trials.  
The significantly reduced prevalence of mild hyperglycaemia following the 
successful exercise-induced mild dehydration is contradictory to the study hypothesis, yet 
there are clear physiological advantages associated with reductions in hyperglycaemia 
prevalence. In the short-term, hyperglycaemia has been shown to negatively affect 
cognitive function and mood (Cryer, 2002; Younk et al, 2011), while an increase in the 
time spent within a hyperglycaemic concentration range is associated with an increased 
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likelihood of a more insulin resistant phenotype and impaired glucose handling. Chronic 
hyperglycaemia or regular glycaemic ‘excursions’ from a euglycaemic concentration 
range is indicative of impaired glycaemic control, and will lead to a progressively 
increased risk of developing micro- and macro-vascular complications including 
retinopathy, nephropathy, neuropathy, cardiovascular disease, along with impairments in 
endothelial function and blood flow (Chimen et al, 2007; Kennedy et al, 2013; Riddell et 
al, 2017). Furthermore, the reduced prevalence of mild hyperglycaemia with no 
concomitant increased risk of hypoglycaemia arising during dehydration trial of the 
current study, for example, is a key factor in the successful management of T1DM. 
Regular or acute hypoglycaemic episodes may affect the patient’s ability to adhere to a 
strict glycaemic management regimen and obtain their desired level of glycaemic control 
(McCrimmon and Sherwin, 2010).  
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Blood vs Libre 
In an additional, novel component of the current study, a tertiary aim was to 
assess any potential differences in compartmental glucose responses during exercise and 
the post-exercise recovery period, via simultaneous measurement of both interstitial 
glucose and venous whole blood glucose concentrations. During the exercise period of 
the dehydration trial, there was a statistically significant difference between the change 
in interstitial glucose concentration and the change in blood glucose concentration at 15 
minutes and 45 minutes from the respective baseline concentrations. There was also a 
significant difference in the change in interstitial glucose concentrations between the 
initial (0 mins) exercise value and 15 minutes into exercise during both experimental 
trials. The peak increase in interstitial glucose concentration not only exceeds, but also 
appears up to 15 minutes after the peak blood glucose response during exercise in both 
trials. However, there were no significant differences in the change from the respective 
baseline glucose concentrations during the post-exercise recovery period in either trial.  
The current study is one of very few to assess fluctuations in interstitial glucose 
concentrations during exercise. Most studies to date have assessed interstitial glucose 
monitor accuracy, including FreeStyle Libre™, in terms of Mean Absolute Relative 
Difference (MARD) against reference venous or capillary glucose concentrations, but only 
under resting, euhydrated conditions (Moser et al, 2018). Aberer et al (2017) previously 
showed that during short, low intensity (2 x 15 minutes) exercise, FreeStyle Libre 
displayed the greatest accuracy against reference venous blood glucose values in 
comparison to selected continuous interstitial glucose monitors (CGM) that were worn 
simultaneously.  
During the current study, the measurement of whole blood glucose concentrations may 
underestimate venous plasma glucose concentrations, potentially accounting for the 
greater difference between blood and interstitial glucose concentrations compared to 
previous research. Although the relatively small number of time-aligned paired interstitial 
and blood glucose concentrations was considered to be a negative outcome of the 
Aberer et al (2017) study, there was an identical number of paired glucose data points 
during the current study, based on an interstitial glucose sampling frequency of 5 minute 
intervals during 60 minutes of exercise.  
 79 
During the initial stages of exercise, the interstitial glucose response has tended to 
be blunted in comparison to the rapidly increasing blood glucose concentration in 
previous studies (Moser et al, 2016). The increase in local blood flow to metabolically 
active skeletal muscles, coupled with the redistribution of extracellular fluids, leads to an 
initial increase in interstitial fluid volume. Furthermore, the rate of glucose transport 
from the capillaries into the interstitial fluid is often insufficient to match the increased 
blood glucose concentration resulting from increased utilization of endogenous glucose 
sources or ingested carbohydrates (Moser et al, 2018). Throughout the exercise period of 
both experimental trials, a physiological lag was evident whereby there was a trend for 
interstitial glucose concentrations to match, or even exceed, the increases in blood 
glucose concentrations during exercise in both trials. The lag in interstitial glucose 
response has been consistently proven due to the time required for glucose to diffuse 
from the capillaries into the interstitial fluid, which itself is determined by alterations in 
local blood glucose concentration and the rate of peripheral cellular glucose uptake by 
metabolically active skeletal muscle (Moser et al, 2018; Ajjan et al, 2018). It is possible 
that the increased cardiac output stimulated by the onset of exercise may affect the 
interstitial glucose response in the upper arm, although upper arm activity is minimal 
during cycle ergometer-based exercise.  
During the current study, it is unclear what physiological mechanisms may be 
responsible for the significant differences in interstitial and blood glucose responses 
particularly evident during the dehydration trial. Moser et al (2016) highlighted that 
prolonged exercise or exercise-induced dehydration may decrease interstitial glucose 
supply compared to venous or capillary glucose levels, although it is unclear the level of 
dehydration necessary to induce alterations in glucose delivery. Furthermore, exercise-
induced dehydration via cycling has been shown to primarily impair extracellular fluid 
regulation, including interstitial fluid volume, to supplement and maintain intramuscular 
and intracellular fluid volumes (Yardley et al, 2013; Siegmund et al, 2017). It is unclear 
how the redistribution of extracellular fluids to maintain critical blood flow to exercising 
muscles may affect any potential changes in interstitial glucose concentration (Yardley et 
al, 2013).  
The majority of research investigating the interstitial glucose response during 
exercise has otherwise assessed the reliability of various CGMs in direct comparison to 
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capillary or venous blood glucose concentrations. Yardley et al (2013) highlighted that the 
changes in interstitial glucose concentration generally underestimated the changes in 
blood glucose concentration during exercise and the subsequent post-exercise resting 
period. Siegmund et al (2017) and Moser et al (2018) completed separate reviews of 
interstitial glucose responses at rest and during exercise along with different sampling 
techniques. Overall, both reviews concluded that if the rate of change in blood glucose 
concentrations exceeded 0.1-0.2mmol/L per minute there were significant differences 
compared to the rate of change in interstitial glucose concentration. Several exercise-
related factors including carbohydrate mobilization/utilization, redistribution of 
extracellular fluids, prandial state and insulin concentration may elicit the magnitude of 
change in interstitial glucose concentration to significantly affect accuracy in comparison 
to aligned blood glucose concentration (Yardley et al, 2013; Siegmund et al, 2017, Moser 
et al, 2018). To date, research is in its infancy regarding the differing mechanisms that 
may affect FreeStyle Libre performance/accuracy during exercise, with all studies taking 
place under euhydrated conditions. Further research is required to establish the exercise-
related factors which may have led to the observed differences in glycaemic response 
and which contrast previous research. For example, the application of the FreeStyle Libre 
to a site on the upper body compared to the lower body would allow for a direct 
comparison in interstitial glucose response based on differences in metabolically-active 
skeletal muscle during exercise, and subsequently increased local blood flow.  
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Applications / Limitations of Research 
Currently, there are no adequate guidelines on hydration requirements during 
and following exercise available for T1DM patients as there is no consideration of any 
potential alterations in glucose concentrations mediated through changes in vasopressin 
concentration. Despite the current evidence which suggests that acute dehydration (i.e. 
increased vasopressin concentration) may have stimulated several metabolic pathways 
which affect glucose metabolism, the current guidelines focus instead on performance 
outcomes, rather than consideration of glucoregulation and T1DM patient’s health. The 
fluid intake guidelines for exercise relate to healthy, non-DM subjects. Hibbert-Jones and 
Regan (2012), Horton and Subauste (2017) and Riddell et al (2017) detail that an 
adequate volume of fluid should be consumed prior to, during and post-exercise to 
prevent dehydration and avoid any negative effects on exercise performance. T1DM 
patients must however ensure stable glycaemic control around exercise for safe, effective 
participation (Riddell et al, 2017). A recent study by Buiote-Stella et al (2018) showed that 
on average, T1DM patients consumed a greater volume of fluid during exercise than the 
guideline intake, and compared with non-DM patients. However, the elevated rate of 
fluid intake did not equate to significant alterations in post-exercise average glucose 
concentrations. Riddell et al (2017) highlight that carbohydrate-electrolyte sports drinks 
may be used to prevent late-onset hypoglycaemia following exercise coupled with 
preventing exercise-induced dehydration, but do not recommend a specific volume of 
fluid to be consumed to optimize glycaemic responses during and following exercise. 
However, there is evidence to suggest that while dehydration may result in an elevated 
glycaemic response during and immediately following exercise compared to euhydrated 
subjects, there may be a prolonged positive effect on glycaemic management observed 
up to 48 hours following mild exercise-induced dehydration. 
Patients with Type 1 Diabetes Mellitus must strike the balance between the 
postulated beneficial effects of acute exercise-induced dehydration on overall glycaemic 
control and the detrimental effect of chronic dehydration on overall health outcomes. 
While dehydration to 1-2% will not affect exercise performance and has been shown in 
the current study to reduce the prevalence of mild hyperglycaemia with a concurrent 
increased in time spent in euglycaemia and avoid hypoglycaemia, prolonged or regular 
dehydration may have negative long-term health consequences. For example, regular 
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dehydration may lead to the development of renal complications, including renal 
nephropathy and perhaps renal failure in extreme circumstances, due to the excessive 
urinary concentrating function associated with chronically elevated vasopressin 
concentrations (Bankir, 2001). Although our study is unable to confirm whether the 
vasopressin-mediated alterations in substrate metabolism are solely responsible for the 
positive effect on glycaemic control, chronically elevated vasopressin concentrations and 
concurrent hyperosmolality are clear risk factors for organ failure and all-cause mortality 
(Bouby et al, 1999; Bankir et al, 2001). Prolonged hyperglycaemia may also impair whole 
body osmoregulation due to the glucose-induced osmotic diuresis stimulated by the 
necessary excretion of excess glucose in the urine (Thompson et al, 1989). Furthermore, 
poorly controlled T1DM has been shown to lead to renal resistance to the effects of 
vasopressin, which may further exacerbate symptomatic polyuria and glycosuria of T1DM 
(McKenna et al, 2000). Overall, poor glycaemic control may foster the development of 
renal complications associated with Type 1 Diabetes Mellitus (Chimen et al, 2007; Younk 
et al, 2011; Riddell et al, 2017).  
The limitations of the current study include no assessment of habitual fluid intake 
prior to beginning the study, or an assessment of total fluid intake during the initial 48 
hour period following each experimental trial, where acute glycaemic control was 
assessed. It is therefore unclear if the degree of dehydration induced via the fluid 
restriction protocol during the current study is sufficient to account for the discrepancies 
in glycaemic prevalence due to acute changes in vasopressin concentration and 
subsequent alterations in glucoregulation. Furthermore, no intramuscular tissue samples 
were obtained to assess any potential changes in skeletal muscle glycogenolysis 
purported following the induction of mild dehydration, and which may aid the 
explanation for increased post-exercise skeletal muscle glycogen resynthesis.  
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In conclusion, the progressive dehydration protocol stimulated a greater 
glycaemic response during and following exercise in mildly dehydrated T1DM patients, 
compared to euhydrated patients, although this was not statistically significant. There 
was also significantly greater serum copeptin and cortisol concentration during the post-
exercise recovery period of the dehydration trial. It is possible that the acutely elevated 
post-exercise glycaemic response of mildly dehydrated T1DM patients was mediated by 
the short-term effects of a transient increase in cortisol concentration on peripheral 
tissues glucose metabolism. Furthermore, although it is likely that the mild levels of 
dehydration induced during the current study were sufficient to stimulate an increased 
rate of skeletal muscle glycogenolysis, further research is required to fully elucidate the 
intramuscular responses to mild levels of hypohydration and whether the rate of 
glycogen replenishment may affect longer-term glycaemic control. Crucially, mild 
dehydration aided acute glycaemic control by ensuring there was a reduction in 
hyperglycaemia prevalence without an additional risk of hypoglycaemia arising. However, 
T1DM patients must balance the effects of regular or prolonged dehydration and the 
subsequent deleterious consequences associated with chronically elevated vasopressin 
concentrations, with the potential for short-term improvements in post-exercise 
glycaemic control. The results of the current study should be considered as relevant, 
informative pilot data to inform future research investigating the effects of variable 
hydration status on T1DM patient glycaemic control. This study was independently 
funded, with the aim to assess the glycaemic responses of an at-risk population and 
incorporated flash glucose monitoring technology and a novel nutritional strategy to aid 
glycaemic control. This is the first study to our knowledge to assess glycaemic responses 
to hydration status in T1DM patients, and is further complicated by the existence of 
equivocal evidence regarding the physiological mechanisms stimulated by alterations in 
hydration status in healthy subjects. There is a clear evidence-based gap in the guidelines 
for fluid intake around exercise for T1DM patients, which are instead aligned with the 
population-wide fluid intake recommendations. For T1DM patients, it is vital that safe, 
effective participation in exercise is maintained via similar nutritional and behavioural 
strategies to avoid glycaemic disturbances during and particularly the hours following 
exercise.  
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Appendix 1: The Effect of a Concomitant Selective Serotonin Reuptake Inhibitor (SSRI) on 
T1DM Patient’s Glycaemic Control- A Case Study 
Background 
Depression is twice as prevalent within the diabetes mellitus (DM) population 
compared to healthy, non-diabetic individuals (Anderson et al, 2001). DM patients 
diagnosed with co-morbid depression are at a significantly greater risk of an elevated 
fasting blood glucose concentration and subsequently greater HbA1c concentration, 
which may result in the development of disease-specific health complications (Lustman 
et al, 2001; Papelbaum et al, 2011). Antidepressants such as Selective Serotonin Re-
Uptake Inhibitors (SSRI) are commonly prescribed to effectively treat depression 
symptoms, but there is equivocal evidence regarding the concomitant effect of 
antidepressants on glycaemic control (Sawka et al, 2001; Derijks et al, 2008; Knol et al, 
2008; Brieler et al, 2016; Radojkovic et al, 2016). Specifically, treatment with SSRI 
medication (e.g. fluoxetine) has been shown to have a prolonged positive effect on long-
term glycaemic management compared to other classes of antidepressant, including a 
discernible reduction in T2DM patient HbA1c concentration and upregulated 
hypoglycaemia counter-regulatory responses with acute SSRI treatment (Briscoe et al, 
2008; Brieler et al, 2016; Radojkovic et al, 2016). However, the effects of antidepressant 
prescription on acute and long-term glycaemic control only have been investigated to 
date, in the absence of any potential effects of exercise on glycaemic control. 
Furthermore, there is little evidence available regarding the effect of antidepressant 
treatment on glycaemic control in T1DM patients, despite the importance of maintaining 
good glycaemic control for the successful management of T1DM (Kennedy et al, 2011; 
Fava et al, 2014).  
 
Case Study Outline 
One T1DM patient, who only managed to complete 50 minutes of exercise on 
both trials despite completing the full exercise protocol in the familiarization trial, was 
withdrawn from the main study. This patient was prescribed a concomitant 
antidepressant medication within the study timeline. To assess any potential 
disturbances in glycaemic control around exercise with prescribed SSRI treatment, this 
patient was selectively examined.  
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Results 
The results of this n=1 case study showed that there was an identical change in 
glycaemic response during exercise in both trials. Interstitial glucose concentration 
increased from the respective baseline values (Control: 8.3mmol/L, Dehydration: 
12.1mmol/L) until the peak glycaemic response, before declining below baseline 
concentrations by the culmination of exercise (Figure 15A). A similar response was 
evident for blood glucose concentration from baseline values (Control: 7.7mmol/L, 
Dehydration: 10.0mmol/L) until the end of exercise (Figure 15B). However, the exercise 
session was prematurely stopped following self-reported feelings of nausea and dizziness 
at the culmination of the initial (dehydration) trial. It is unclear whether the SSRI 
treatment affected the participant’s awareness of hypoglycaemia-related symptoms, as 
there was no apparent threat of hypoglycaemia based on the participant’s interstitial and 
blood glucose concentrations. Each of these symptoms is a primary side-effect of 
commencing SSRI treatment (Ferguson, 2001). The participant previously completed the 
entire familiarisation session safely, including the full duration (60 minutes) of the 
exercise protocol, prior to beginning the SSRI treatment. During the post-exercise 
recovery period, there was an elevated glycaemic response evident in the dehydration 
trial in contrast to the control trial, where both interstitial and blood glucose 
concentrations tended to remain below the respective baseline concentration 
(Interstitial: 6.2mmol/L; Blood: 5.5mmol/L). Interstitial and blood glucose concentrations 
tended to remain elevated above baseline concentrations (Interstitial: 6.5mmol/L; Blood: 
7.3mmol/L) during the post-exercise period of the dehydration trial only.   
There was an additional unit of insulin required pre-exercise during the 
dehydration trial, coupled with a further bolus unit of insulin administered during the 
post-exercise recovery period to prevent severe hyperglycaemia. In contrast, 27g of 
additional carbohydrate was required to prevent hypoglycaemia during the post-exercise 
period of the control trial.  There was an increased prevalence of hypoglycaemia evident 
up to 24 hours following both trials in this patient, compared to the rest of the T1DM 
patient sample who completed both experimental trials (20% vs 5% control trial, 12% vs 
5% dehydration trial, respectively). In general, >75% total interstitial glucose 
concentrations were within hypoglycaemic or euglycaemic concentration ranges for the 
treated subject following the control trial, compared to ~30% on average for the 
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untreated T1DM patient sample. The dehydration protocol successfully induced a greater 
increase in circulating post-exercise copeptin concentrations from baseline values, 
compared to the control trial (Table 5). Cortisol concentrations decreased over time 
across both trials, with a tendency for an elevated cortisol concentration during the 
dehydration trial (Table 5). Finally, glucagon concentrations were evidently greater 
throughout the control trial, compared to time-aligned values during the dehydration 
trial. However, there was a significant decline in glucagon concentrations by the 
culmination of the post-exercise period during both trials (Table 5).  
 
Discussion 
 To our knowledge, this is the only data available that has assessed glycaemic 
control specifically around exercise in conjunction with concomitant antidepressant 
treatment in patients with T1DM. Previous studies by Sanders et al (2008) and Briscoe et 
al (2008) showed an upregulated counter-regulatory response to individual or repeated 
episodes of hypoglycaemia in both non-diabetic and T1DM patients respectively with 
extended SSRI treatment. Although glucagon concentration was elevated at baseline 
during the control trial, the sampling timeline does not allow for an accurate assessment 
of glucagon response to the threat of hypoglycaemia arising during the post-exercise 
recovery period of the control trial. However, there was a significant decline in glucagon 
concentration evident during the control trial from the immediate post-exercise 
concentration to the 2 hours post-exercise value. It is therefore likely that the 
dysregulated alpha cell function, and overall impaired counter-regulatory response to 
potential hypoglycaemia is unaffected by short-term SSRI prescription. Previous research 
to date has allowed for a greater duration of SSRI treatment prior to assessing 
hypoglycaemia counter-regulatory responses under resting conditions. Our interpretation 
of the current case study is limited by the incomplete dietary intake and insulin 
administration post-trial diaries following each experimental trial for this T1DM patient 
only. It is possible that changes in post-exercise glycaemic management, based on the 
glucose responses during each experimental trial, may explain the discrepancies in 
prevalence of hypoglycaemia and hyperglycaemia up to 24 hours following each 
experimental trial, compared to the non-SSRI treated T1DM patient cohort. Overall, there 
appeared to be a greater risk of hypoglycaemia following both experimental trials 
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compared to the untreated T1DM cohort, with an evident glucose lowering effect in the 
24 hours particularly following the control trial. It is unclear whether the impaired 
hypoglycaemia counter-regulatory response to exercise associated with T1DM (Diedrich 
et al, 2002) may impact the proposed SSRI-mediated increase in counter-regulatory 
hormone secretion. 
Further research is required to include an assessment of glycaemic control around 
exercise with acute and chronic SSRI treatment, as the only exercise-related outcome to 
have been previously reported is an increased adherence to regular exercise with chronic 
SSRI treatment (Lustman et al, 2011).  
 
 
Table 5: Time-aligned endocrine responses of SSRI-treated T1DM patient prior to and 
post-exercise, where the patient was either euhydrated (control) or were wholly fluid 
restricted (dehydration trial).  
Time Cortisol (pg/mL) Glucagon (pg/mL) Copeptin (pmol/L) 
Control Dehydration Control Dehydration Control Dehydration 
Baseline  
(Pre-Exercise) 
59280 80550 8.93 4.27 3.87 8.60 
0hrs Post-
Exercise 
33930 59280 10.70 3.25 6.50 35.45 
2hrs Post-
Exercise 
19870 14200 1.00 1.00 2.63 12.62 
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Figure 15: Changes in the (A) interstitial glucose concentration and (B) blood glucose concentration of a T1DM patient prescribed ongoing 
SSRI treatment, during exercise and throughout the post-exercise recovery period of both the control trial and dehydration trials. Interstitial 
glucose concentration was measured at 5 minute intervals throughout each experimental trial, with blood glucose measurements obtained 
every 15 minutes during exercise and the first hour of recovery. During exercise, the baseline (resting) value (R) was taken as the pre-
breakfast glucose concentration. Initial post-exercise (0 mins post-exercise) glucose value was then considered to be the baseline 
concentration for the calculation of changes in glucose concentration during the post-exercise recovery period.  
R 0 5 10 15 20 25 30 35 40 45 50 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95100105110115120
-6
-4
-2
0
2
4
6
8
Time (mins)
D
  
B
a
s
e
li
n
e
 G
lu
c
o
s
e
 (
m
m
o
l/
L
)
Control
Dehydration
Exercise
Recovery
A
R 0 5 10 15 20 25 30 35 40 45 50 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100105110115120
-4
-2
0
2
4
Time (mins)
D
  
B
a
s
e
li
n
e
 G
lu
c
o
s
e
 (
m
m
o
l/
L
)
Control
DehydrationExercise
Recovery
B
 100 
Appendix 2: Intra-Monitor Comparison of FreeStyle Libre Performance  
In contrast to the multitude of studies that have investigated interstitial glucose 
responses against reference blood glucose concentrations (Yardley et al, 2013; Luijf et al, 
2013; Moser et al, 2016; Fokkert et al, 2017; Aberer et al, 2017), there is little evidence 
available regarding the inter-reliability of flash interstitial glucose monitors applied to 
opposing anatomical sites (left and right upper arm). Participants (n=9) were fitted with 
an additional flash interstitial glucose monitor (FreeStyle Libre) on their vacant arm 
prior to the control trial only to investigate any discrepancies in the glycaemic response 
of interstitial glucose monitors worn simultaneously during and following exercise under 
euhydrated conditions.  
The results highlighted a trend for an elevated interstitial glucose response 
throughout exercise with the monitor most recently applied prior to the experimental 
trial (Monitor 2, Figure 16). However, there was no statistically significant difference in 
either the pre-exercise baseline interstitial glucose concentrations between trials 
(Monitor 1: 9.7mmol/L, Monitor 2: 9.8mmol/L; p>0.05), nor the glycaemic response of 
each flash glucose monitor from the respective baseline concentrations during exercise 
(p>0.05). During the post-exercise recovery period, there was also no significant 
difference in baseline post-exercise interstitial glucose concentration between trials 
(9.0mmol/L vs 10.2mmol/L; p>0.05). Furthermore, there was no statistically significant 
difference in interstitial glucose response between monitors from the respective post-
exercise baseline concentrations (p>0.05). Assessment of acute glycaemic control showed 
no significant difference in the average interstitial glucose concentrations collated for 
each monitor at hourly intervals up to 48 hours following the respective experimental 
trials (Figure 17, p>0.05).  
Bailey et al (2015) conducted the only other study to date which has directly 
assessed the accuracy of two FreeStyle Libre™ monitors worn simultaneously on the 
upper left and right arm. The results concur with the current study, whereby there was 
no significant difference between the accuracy of the flash glucose monitors on opposing 
sites, where sensor accuracy was expressed as the Mean Absolute Relative Difference 
(MARD) from capillary and venous whole blood glucose concentrations.   
There may be differences in flash interstitial glucose monitor sensor 
activity/accuracy between initial application and when nearing the end of the 14 day 
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wear period, but there was no effect on the interstitial glucose responses between 
monitors evident during the current study. In vivo analysis of FreeStyle Libre™ monitor 
sensitivity to changes in reference capillary blood glucose concentrations across the 
entire 14 day wear period under free-living conditions confirmed that there was no 
significant decrement in sensor sensitivity after Day 1 (Hoss and Budiman, 2017). Initial 
local inflammation around the insertion site has previously been shown to affect 
interstitial glucose concentrations within the first 24 hours of flash interstitial glucose 
monitor application (Bailey et al, 2015).  
Previous attempts to assess the inter-reliability of the FreeStyle Libre monitor 
have applied the sensor in locations which may have compromised the interstitial glucose 
response (Siegmund et al, 2016). A FreeStyle Libre monitor applied to the upper rear of 
one arm was significantly more accurate against reference capillary blood glucose 
measurements in comparison to a monitor applied on the abdomen, following the 
ingestion of a carbohydrate bolus (Fokkert et al, 2017). However, Hoss and Budiman 
(2014) have shown that under free-living conditions, there was no significant difference 
in monitor sensitivity between monitors applied to applied to the arm and the abdominal 
wall.  
The current study is the first to our knowledge to assess the accuracy of 
simultaneous FreeStyle Libre monitors in response to exercise. Previous research has 
detailed the fluctuations in interstitial fluid volume and composition with exercise, and 
the subsequent effects on interstitial glucose concentrations (Moser et al, 2017; 
Siegmund et al, 2016). Despite potential differences in posture when simultaneous 
venous blood glucose sampling in one arm was undertaken along with interstitial glucose 
sampling during exercise, there was no significant difference in interstitial glucose 
responses between monitors during exercise. Further research is required to accurately 
assess potential variations in flash interstitial glucose monitors worn simultaneously 
during differing modes of exercise, with variable fluid intake or with short-term, rapid 
changes in interstitial glucose concentration to fully assess the accuracy of flash 
interstitial glucose monitors worn simultaneously (Ajjan et al, 2018).  
The results of the current case study, coupled with previous research, do indicate 
that application of the FreeStyle Libre to the preferred site as per the manufacturer’s 
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instructions will result in equally reliable interstitial glucose measurements, independent 
of the arm selected, during continuous, moderate intensity exercise.  
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Figure 16: Intra-monitor comparison of the mean interstitial glucose response obtained from individual flash interstitial glucose monitors 
(FreeStyle Libre™) during the exercise and post-exercise recovery period of the control experimental trial. Each glucose monitor was 
scanned at 5 minute intervals throughout the experimental trial. During exercise, the baseline (resting) concentration (R) is represented by 
the pre-breakfast interstitial glucose concentration. Initial post-exercise (0 mins post-exercise) glucose concentration is represented by the 
baseline interstitial glucose concentration during the post-exercise recovery period. All data presented as Mean ± SEM. 
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Figure 17: Mean interstitial glucose concentrations collated over 1 hour intervals during the 48 hours immediately following the control 
experimental trial for individual flash interstitial glucose monitors (FreeStyle Libre™) applied to opposing sites on the upper arm. The shaded 
area of the graph denotes each overnight period. Each arrow indicates the mean timepoint at which a main meal was consumed during the 
48 hour period following each experimental trial. Data presented as the mean glucose concentration at each timepoint for each interstitial 
glucose monitor, with a pooled SEM shown in the top left of the figure.            
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Appendix 3: Diabetes Self-Management Questionnaire 
 
The following statements describe self-
activities related to your diabetes. Thinking 
about your self-care over the last 8 weeks, 
please specify the extent to which each 
statement applies to you 
Applies 
to me 
very 
much 
Applies 
to me to 
a 
consider
able 
degree 
Applies 
to me to 
some 
degree 
Does not 
apply to 
me 
1. I check my blood sugar levels with care and attention    3 2 1 0 
2. The food I choose to eat makes it easy to achieve optimal 
blood sugar levels 
3 2 1 0 
3. I keep all doctors’ appointments recommended for my 
diabetes treatment 
3 2 1 0 
4. I take my diabetes medication (e.g. insulin, tablets) as 
prescribed 
3 2 1 0 
5. Occasionally I eat lots of sweets or other carbohydrate-rich 
foods 
3 2 1 0 
6. I record my blood sugar levels regularly (or analyse the value 
provided with my blood glucose monitor/meter) 
3 2 1 0 
7. I tend to avoid diabetes-related doctors’ appointments 3 2 1 0 
8. I do regular physical activity to achieve optimal blood sugar 
levels 
3 2 1 0 
9. I strictly follow the dietary recommendations given by my 
doctor or consultant diabetes specialist 
3 2 1 0 
10. I do not check my blood sugar levels frequently enough as 
would be required for achieving what is deemed good blood 
glucose control 
 
3 
 
2 
 
1 
 
0 
11. I avoid physical activity, although it would improve my 
glycaemic control 
3 2 1 0 
12. I tend to forget to take or skip my diabetes medication (e.g. 
insulin, tablets) 
3 2 1 0 
13. Sometimes I have real ‘food binges’ (not triggered by 
hypoglycaemia) 
3 2 1 0 
14. Regarding my diabetes care, I should see my medical 
practitioner(s) more often 
3 2 1 0 
15. I tend to skip planned physical activity 3 2 1 0 
16. My diabetes self-care is poor 3 2 1 0 
 
Scoring of the DSMQ: 
The questionnaire is comprised of 4 sections: 
• Glucose Management (Qs 1, 4, 6, 10, 12) 
• Dietary Control (2, 5, 9, 13) 
• Physical Activity (8, 11, 15) 
• Health Care Use (3, 7, 14) 
 
For each section: (total score / maximum score possible) x 10 = transformed score 
(N.B. where negatively worded questions apply, the score is inversed 
         e.g. score of ‘0’ for Q regarding avoidance of appointments would be considered as 
a ‘3’) 
 
The greater the total transformed score (sum of total for each section), the more 
effective the self-management of Diabetes Mellitus. 
